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CHAPTER 1: BACKGROUND AND SIGNIFICANCE 
Epidemiology and Etiology of Basal Cell carcinoma: 
Skin Cancer is the most common cancer in humans. Cancer statistics reveal 
that incidence of skin cancer increases annually, making this cancer a growing 
public concern [1]. The two main types of skin cancer are Melanoma, which is the 
most aggressive and lethal form and accounts for about 4% of skin cancers, and 
Non melanoma skin cancer (NMSC). NMSC consists of many subtypes. The two 
major subtypes are squamous cell carcinoma SCC (16%) and Basal cell carcinoma 
BCC (80%)[2]. BCC is rarely fatal and metastatic, less than 0.5% of BCC were 
reported to metastasize in distal locations. However, the economic burden of BCC is 
one of the highest due to its high prevalence with more than one million case 
reported in the US. In spite of the relatively low mortality and metastasis rate, the 
disease has been considered to be a public health issue due to its high frequency 
and recurrence which increases morbidity caused by this disease [1, 3].  
NMSCs are predominantly diseases of the Caucasian population as they are 
especially prevalent in this ethnic group, mainly in areas of higher sun exposure[1]. 
Despite its relatively low incidence in Black, Hispanic and Asian groups, BCC is still 
the most common skin cancer in these populations. Besides, there are differences 
between Caucasian and non-Caucasian populations in the anatomical location of 
the tumors, in their recognized etiologic factors and in prognosis [4]. 
Despite the increasing incidence of the disease in the younger population, 
BCC is considered to be the disease of the elderly as the majority of patients 
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diagnosed with this type of cancer are over 65 years of age. [1]. Skin cancer is 
predominantly found in light-skinned Caucasians especially Type1and type 2 skin, 
according to Fitzpatrick photo-typing [5]. Men were found to have higher incidence 
and death rate of BCC comparing to women [1]. In general, the low socioeconomic 
groups have less incidence of skin cancer than the higher socioeconomic groups, 
but with lower survival rates and poor outcome [6], probably related to late diagnosis 
due to lower accessibility of health care. Also, it was shown that incidence of BCC is 
related to lack of UV protection during sun exposure, which may not be a priority for 
lower socioeconomic population due to lack of awareness or financial resources. 
Interestingly, an increase in prevalence of BCC among girls is emerging, especially 
among high socioeconomic group. This increase is linked to frequent intentional 
tanning. This procedure requires high exposure to UV light, which  was recognized 
as a major risk factor for BCC [7].  
ALL types of NMSC, including BCC and SCC, are more common in immune-
compromised patients. This includes patients who are taking immune suppressant 
drugs such as organ transplant patients, and is unfortunately associated with a more 
aggressive growth, higher risk of metastases, and poor outcome expectancy [2]. 
Despite high recurrence rate in BCC, multiple primary BCC lesions can be caused 
by genetic syndromes. For instance, Gorlin-Goltz syndrome is usually characterized 
by multiple basal cell carcinoma and keratocystic tumors along with other skeletal 
abnormalities [8]. 
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 Pathology and Pathophysiology of Basal Cell Carcinoma:  
The vast majority of sporadic basal cell carcinoma lesions appear in areas of 
the body that are frequently exposed to sun. The risk of developing BCC is not only 
directly associated with UV exposure during adulthood, but it is also linked to 
appearance of freckles and frequent incidence of sunburns during childhood[5].   
In literature, BCC has been associated with some genetic factors. For 
instance, the majority of BCC cases are associated with mutations in hedge-hog 
pathway. Some of these mutations were reported to be in sonic hedgehog gene, 
others were found in PTCH or SMO receptors [9]. Other genetic mutations that were 
typically found in BCC are in P53 tumor suppressor gene, Ras oncogene, and 
RUNX3 transcription factor encoding gene [5, 10]. Syndromes that include BCC 
were related to genetic polymorphisms, especially when multiple tumors form 
simultaneously in different areas including the trunk that is not highly exposed to 
sun. Some of these polymorphisms that were associated with BCC were found in 
glutathione S-transferase, NADPH and cytochrome P-450. In other cases, trisomy of 
chromosome 6 was associated with genetic predisposition to BCC and was 
associated with more aggressive tumor growth[5].  
Early stages of BCC tumor appear like a small flat or raised sore of the skin 
that never heals and grows slowly. It can look translucent or pearly, usually 
surrounded by superficial vessels, and can bleed easily[5]. In medical literature 
there are six subtypes of BCC that are well defined and classified. Subtypes of BCC 
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include nodular, superficial, pigmented, morpheaform, cystic and 
fibroepithelioma[11]. These subtypes differ in their appearance and aggressiveness. 
The superficial and the nodular are considered to be less aggressive subtypes, 
while higher aggressiveness is usually associated with the infiltrative, the 
micronodular and the morphoeic subtypes of BCCs.  
Histologically, BCC tissue appears to have a hyper-chromatic nucleus 
surrounded by little cytoplasm with no variation in size and staining density. The 
intercellular bridges are not well defined and they can be hardly recognized by 
regular microscopes. BCC mass is lined by a fibromyxoid stroma with a lot of 
collagen fibers and air bubbles [11]. The prognosis of basal cell carcinoma is 
dependent on early detection and availability of treatments. However, survival rate is 
100% in patients with un-metastasizing BCC. Once it metastasizes the prognosis 
becomes very poor.  
The risk of metastasis in BCC is related to the size of the tumor. Among BCC 
tumors that are at least 3 cm in diameter, only 2% metastasize. while 50% of BCC 
tumors that are greater than 10 cm form metastasis [5]. However, when BCC tumor 
does not metastasize, it practices local invasion to surrounding tissue. When not 
diagnosed at early stages, BCC can cause severe deformity which  may leads to 
morbidity or  impact the patient’s quality of life after the treatment [5].  
Vitamin D and its metabolism: 
     Vitamin D is a fat soluble vitamin. It is the only vitamin that can be obtained from 
diet or can be biosynthesized in skin keratinocytes from precursors in response to 
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sun exposure. The term refers to a group of antirachitic steroid derivatives with 
similar biochemical activity. It is present in the diet from animal or plant sources as 
vitamin D2 (ergocalciferol). Additionally, it is synthesized in the skin as vitamin D3 
(cholecalciferol) from 7-dehydrocholesterol, which is present in abundance, by the 
action of 290-320 nm UVB radiation.  
Vitamin D3 is regulated in the body through different steps of activation and 
inactivation that maintain adequate levels of the active form in blood and. In the first 
step of activation, Vitamin D3 precursors, Cholecalciferol is hydroxylated in the liver 
to form hydroxycholecalciferol or 25 hydroxyvitamin D3 [12, 13], or calcidiol. This 
step is carried out by VD3 25-hydroxylase (CYP27A1) enzyme which catalyzes the 
reaction of binding a hydroxyl group to vitamin D precursor at carbon number 25 
producing 25(OH) VD3. This form of vitamin D is the major form of vitamin D in 
blood stream and majority of vitamin D reservoir in the body is in that form. Even 
though this form of vitamin D has some activity at the bone and intestine level, it 
accounts for only 1% of the potency of the final biologically active hormone [12]. The 
hormonal form of vitamin D is 1, 25-dihydroxycholecalciferol, or calcitriol, which is 
formed after further hydroxylation in the kidney by the renal enzyme 25 OH VD31α-
hydroxylase (CYP27B1) [12, 13].  
Interestingly, In addition to liver and kidney, keratinocytes express VD3 25 
hydroxylase and 25 OH VD3 1α-hydroxylase. This indicates the presence of both 
vitamin D biosynthesis and activation pathways in skin, showing the skin’s ability to 
supply its own 1,25 hydroxyvitamin D when exposed to UV light [14]. Hence, skin is 
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of unique importance in the synthesis, storage, and release of vitamin D into the 
circulation [11]. Exposure to sunlight a few times a week can reduce the risk of 
osteoporosis, osteomalacia, muscle weakness and fractures [15]. 
 The hormonal active form of vitamin D, 1,25 (OH)2 vitamin D (calcitriol),  is a 
potent seco-steroid that acts by binding to an intranuclear receptor, the vitamin D 
receptor (VDR) present in target tissues of most cells and tissues in the body [16-
18]. The abundance of the active form of vitamin D is regulated not only by 
activation of cacidiol, but also by inactivation by calcitriol. This inactivation is 
mediated by another renal enzyme called 25-Hydroxyvitamin D-24 hydroxylase 
(24OHase), and it is also a cytochrome P450 enzyme (CYP24A1). Besides the renal 
tissue, this enzyme was found to be produced in keratinocyte. 24OHase can 
regulate vitamin D activity by initiating inactivation pathways for both calcidiol and 
calcitriol. This enzyme can be induced by high levels of the active form of vitamin D 
(1,25(OH)2D3), so it protects the body from excessive production of the hormonal 
form of vitamin D[19].  
Vitamin D and cancer: 
          There is a theory of that the severity of cancer could be reduced by oral 
supplementation of vitamin D [20]. Vitamin D may play a role in the development 
and progression of a wide spectrum of cancers [21, 22]. Prostate cancer [19,16], 
non-small cell lung cancer [18], colorectal cancer [23, 24], breast and ovarian cancer 
[20], [25, 26] are some of the cancers associated with vitamin D metabolism.  
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Nevertheless, although skin cancer is the most common cancer in humans, 
the relationship between skin cancer and vitamin D is not clear [4]. Exposure to 
solar radiation is the main risk factor for the development of NMSC. Ultraviolet 
radiation B (UVB) acts as the carcinogenic agent inducing DNA damage [3]. 
On the other hand, Vitamin D biosynthesis in the skin and the DNA damage 
are both induced by the same spectrum of UVB radiation [3]. Vitamin D was found to 
possess anti-proliferating and pro-differentiating effect [27]. A beneficial role of 
vitamin D in cancer prevention has been reported. This fact led to the theory that 
vitamin D biosynthesis in keratinocytes upon UVB exposure is potentially a defense 
mechanism against cancer [2, 3].  
However, Epidemiological studies failed to provide strong consistent 
evidence for the anticipated benefit of vitamin D supplementation. Some studies 
suggested a protective effect of vitamin D [28]. At the same time, other studies 
concluded a positive correlation between pre-diagnostic serum levels of vitamin D 
and the incidence of BCC [3]. For instance, a cohort study was conducted by Henry 
ford hospital epidemiology group. Participants were 3223 NMSC patients who were 
diagnosed between 1997 and 2009. Results suggested a positive correlation 
between serum levels of Vitamin D and developing NMSC, and the observed 
association was stronger with BCC than with SCC [29]. Many other studies reported 
no association between  vitamin D intake and the development of skin cancer 
including the Nurses’ Health Study [27]. Besides, a prospective case-control study 
assessing  the relation between pre-diagnostic serum levels of 1,25-(OH)2 D3 and 
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subsequent development of malignant melanoma (MM), failed to show significant 
differences between cases and controls [30]. Another case-control study 
investigated the relation between MM and dietary factors. Results showed no 
association between melanoma risk and total vitamin D intake, calorie-adjusted 
vitamin D intake, consumption of milk or vitamin D supplementation [31]. 
Furthermore, a cohort study  investigated the association between BCC and diet 
including dietary fat and vitamins (A, C, D and E), and showed no association 
between these nutrients intake and BCC [32]. 
Several Laboratories investigated the effects of calcitriol (1, 25 (OH) 2 D3) in 
cellular physiology. Calcitriol was shown to be involved in multiple cellular 
mechanisms that include calcitriol or was shown to be involved in multiple cellular 
mechanisms that include cellular growth, differentiation [33, 34], malignant cellular 
invasion, apoptosis [16, 35], including UV induced apoptosis [34] and immune 
modulation. In fact, calcitriol is one of the most potent regulators of cellular growth in 
both normal and cancer cells [17]. The local production of calcitriol is postulated to 
be important for regulating cell growth and therefore possibly preventing the cell 
from becoming autonomous and developing into a unregulated cancer cell [17]. 
Additionally, in vitro studies have shown increased expression of vitamin D 
receptor (VDR) in BCC [36], SCC [16] and MM [35] as well as increased expression 
of mRNA of the main metabolites and enzymes involved in calcitriol metabolism in 
BCC [36, 37] and SCC [16, 37]. However, the function of the VDR in SCCs is 
unknown [16]. Furthermore, combination of 1,25 hydroxyvitamin D and retinoids has 
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been reported to be effective in the treatment and prevention of cancerous and 
precancerous skin lesions, such as actinic keratosis, SCCs, cutaneous T-cell 
lymphomas and BCCs [16]. Studies done on Vitamin D receptor (VDR) null mouse 
models show increased SCC’s when exposed to UVB, portraying a protective  role 
of VDR [38].  Additional studies show that Vitamin D and VDR are protective against 
UVB induced skin cancer by altering signaling pathways and promoting DNA 
damage response [38]. 
A large number of analogues of 1,25 hydroxyvitamin D with potent anti-
proliferative and pro-differentiating effects on cancer cells in vitro have been 
developed and tested in animal models and a small number of human studies. 
Calcipotriol, an analogue has been evaluated for topical treatment of advanced 
breast cancer. A phase I clinical trial in patients with advanced breast and colon 
cancer has been completed in the United Kingdom without evidence of clear 
antitumor effects. Phase I/II clinical trials are currently underway in patients with 
breast, pancreatic, hepatocellular carcinoma and myelodisplasia [13]. Therefore, the 
exact role played by Vitamin D in skin cancer is still inconclusive which calls for 
more direct approach to determine the biological role of Vitamin D in the 
development of several types of cancers including  colon cancer and skin cancer 
[39, 40] .  
The Institute of Medicine recommended that the daily allowance for vitamin D 
should be 15 μg (600 IU). However, the RDA  for seniors above 70 years old was 
increased to 20 μg (800 IU), with the safe upper limit set at 100 μg (4,000 IU) for all 
10 
 
 
 
adults [41]. However, it has been largely accepted in clinical practice that 
administrating large doses of vitamin D to skin cancer patients is recommended as 
part of any treatment and/or prevention regimen 
Vitamin D and mTOR pathway: 
    The mammalian target of rapamycin (mTOR) is an important cell signaling 
protein and it plays a role in many important cellular functions. mTOR impact the 
regulation of cell growth, cell cycle, nutrient status, as well as many transcription and 
translation factors in the cell [42]. mTOR is considered  serine/threonine protein 
kinase that belongs to the (PIKK) family. This protein is large and consists of 
multiple domains that forms two distinct complexes called TORC1 and TORC2. 
mTOR is highly conserved among many species, that we can find similarity in the 
structures and the functions between mTOR in humans, rats, mice and TOR in 
plants, drosophila and even fungi [43, 44]. The tow TOR complexes are composed 
of different domains and hence possess different functions and roles. For instance, 
Only TORC1 can bind to Rapamycin but not TORC2. 
mTOR regulates different cellular functions through interacting with different 
pathways. For example, it impacts translation of some proteins related to cellular 
growth in response to amino acids, especially the branched amino acids, through 
interaction with PI 3K signaling. On the other hand, mTOR regulates the translation 
of other proteins through the phosphorylation of pS6K and 4E-BP1, which result in 
activation of the first one and inhibition of the later [44].  
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 Many mechanistic studies suggested that Vitamin D can exert differentiation 
and inhibits proliferation of cancer cells by blocking mTOR through increasing 
REDD1, which is mTOR inhibitor [45-47].  
mTORC1 is part of a vital regulatory pathway in the cell which is Ras-PI3K-
AKT-mTOR pathway. mTOR responses are initiated by PI3K impacts mTOR 
pathway through Akt which is serine/threonine kinase. AKT is activated by 
Phosphorylation in two locations serine 473/threonine 308 which in turn 
phosphorylates and inhibits the activity of TSC1/2 (tuberous sclerosis protein 
complex). TSC complex inhibition results in suppression of Rheb protein (Ras 
homolog enriched in brain), which increases the activity of mTOR complex [47]. 
mTOR itself is a protein kinase that influence cell cycle regulation, cellular growth, 
metabolism, and autophagy by phosphorylation of two essential proteins. The first 
one is 4E-binding protein (4E-BP) that is involved in initiation of ribosome 
biogenesis. The second protein that gets phosphorylated by mTOR is ribosomal 
protein S6 kinase (p70S6K) impacting protein synthesis [45, 47]. mTOR 
phosphorylates TIF4E-binding protein (4EBP), impairing its ability to bind to TIF4E 
protein. P-4EBP and p-S6K can be used as indicators of mTOR signaling [48] . 
VDR is known to negatively regulate mTOR through up-regulating REDD1 
(regulated in development and DNA damage response 1) protein. The gene 
encoding REDD1 protein is VDR target gene that contains VDRE in its promoter 
[45]. Up-regulation of this gene is known to block the activity of mTOR  gene through 
promoting the activation of TSC1/2 complexes, which in turn inhibits Rheb resulting 
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in suppression of mTOR activity [47]  . VDR effect on its target gene transcription 
regulation was shown to be impaired when some proteins called VDREBP (vitamin 
D response elements binding proteins) are up-regulated as they compete with VDR 
over the binding sites of its response elements in the promoter of the target gene 
Protein analysis shows that REDD1 is successfully up-regulated in cancer tissue 
despite the elevation in VDREBP.   
Active AKT is known to block the assembly and activation of TSC1/2 complex 
which opposes with the effect of VDR. Up-regulation of PI3K-AKT-mTOR pathway 
was shown in many other cancers such as breast cancer, and it was anticipated to 
alter the cancer response to endocrine treatments [48, 49]. Upstream of this 
pathway there is Ras gene which is an oncogene and was reported to have gain of 
function mutations which result in up-regulating two main pathways, PI3K-AKT-
mTOR and Ras-Raf-MEK-ERK pathway [50]. Ras point mutations are common, and 
were repeatedly reported in many types of cancers including, but not limited to, 
colon, skin, and breast cancers [51]. 
Hh-Gli pathway and basal cell carcinoma: 
PTCH receptor is a plasma membrane receptor that is integrated in the 
phospholipids bi-layer of the membrane. The normal function of PTCH is to bind and 
inhibit another plasma membrane receptor called smoothened (SMO). This binding, 
and hence the blocking of SMO is released after PTCH receptor binds to its ligand 
(Hedgehog) protein [46]. Over expression of this pathway may result from over 
expression of the Hh ligand causing continuous suppression of PTCH receptor, or 
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from truncation of the PTCH receptor resulting in failure to bind to SMO, and 
sometimes from a gain of function mutation in SMO itself [52]. SMO, when unbound, 
can activate a signal transduction pathway that result in over expression of 
downstream glioblastoma Gli1 and Gli2 signaling proteins [52, 53], and switching the 
Gli code to the transcription activation mode [54]. 
Gli code system involves three transcription factors Gli1, Gli2, and Gli3. 
These three proteins cooperate to regulate cellular function in response to upstream 
signals [54]. Gli1 is the main transcription activator, while Gli3 is a transcription 
repressor. Gli2 can operate as either activator or repressor, depending on the level 
of C-terminal cleavage [53]. Gli2 and Gli3 possess a transcription repression 
function only in the cleaved form. Gli2 turns to a transcription activator when it is not 
cleaved, and non-cleaved Gli3 is inactive [54]. Hedge-hog signaling pathway 
controls the expression of Gli1 and the cleavage of Gli proteins, resulting in 
switching the Gli-code between the transcription inhibition and the activation modes 
[53]. In presence of Hh protein, SMO is active. Consequently, Gli1 is 
transcriptionally expressed and the cleavage is inhibited, rendering Gli-code in the 
transcription activation mode [9, 54]. On the other hand, when SMO is inhibited by 
PTCH, Gli1 becomes transcriptionally inactive. Also, Gli2 and Gli3 will be expressed 
and cleaved. In this case, Gli-code is in the transcription inhibition mode [53, 54] 
 Gli1 target genes are critical for cellular regulation and growth control. For 
instance, up-regulation of Gli1 increases the expression of transforming growth 
factor-β (TGF-β) and epidermal growth factor (EGF) [53, 55]. Over expression of 
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Gli1 is common in many types of cancers as it facilitates the rapid growth of the 
cancer [54]. Up-regulation of un-cleaved Gli2 results in over expression of the anti-
apoptotic protein bcl-2[52]. Elevated levels of bcl-2 can block the intrinsic apoptosis 
pathway [35].  
Hedge-hog pathway mutations characterize basal cell carcinoma, resulting in 
excessive signaling of the pathway [46]. Over-expression of Hh-Gli pathway results 
in modifying the Gli-code, and affects tumor progression and recurrence [53, 56]. 
Some studies discussed vitamin D ability to inhibit Hh-Gli pathway signaling and 
promote differentiation [46], and facilitate alterations in the Gli-code [46, 53]. 
Interestingly, down-regulation of Hh-Gli signaling by vitamin D is independent from 
its nuclear receptor VDR [57]. In fact,  PTCH utilizes the active form of vitamin D and 
its derivatives for SMO inhibition [58]. What is more, vitamin D supplementation to a 
hedgehog mutant mouse was shown to reduce Hh-Gli signaling [56]. These results 
support the expected benefit from supplementing BCC patients with high doses of 
vitamin D.     
Hypothesis and Specific Aims: 
Cancer in general is an increasing problem. Basal cell carcinoma has the 
highest incidence and recurrence, and thus the greatest economic burden [1, 3]. 
Many factors were shown to impact the risk for developing BCC such as age, 
gender, ethnicity, socioeconomic status, and  sun exposure [1].  Vitamin D can be 
obtained from diet or biosynthesized in keratinocytes. Vitamin D3 synthesis from its 
precursor (7-dehydrocholesterol) is initiated by exposure to UVB radiation of wave 
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length between 290-320 nm [3]. The correlation between this exact range of 
radiation with onset of skin cancer raised many controversies related to the benefit 
of sun exposure [3, 7] .  
Vitamin D is known to have an anti-proliferative and pro-differentiating effect 
through impacting some signaling pathways in the cell [28, 29]. Vitamin D3 activates 
its nuclear receptor VDR which hetero-dimerize with RXR and operates as a 
transcription factor[59]. Upon binding to a specific response element in the gene’s 
promoter and recruiting the required co-activators, VDR initiates the transcription of 
the target gene [60].  
It was shown that Up-regulation of VDR target gene REDD1 results in 
negative regulation of mTOR via activating TSC1/2 complexes [45]. Down-regulation 
of mTOR pathway signaling results in reduced 4EBP and S6K phosphorylation, 
which consequently reduces cellular growth and proliferation  [45, 47].  
Vitamin D was also shown to have anti-proliferation activity by down-
regulating hedgehog-Gli pathway signaling in a VDR independent fashion [57].  
Binding of Hh protein ligand to PTCH receptor blocks its ability to inhibit SMO 
receptor. Continuous activity of SMO leads to up-regulating Gli1 and shifting the Gli 
code to the transcription activation mode [53]. Research illustrated that PTCH 
inhibits SMO through vitamin D3 and its derivatives [58]. Supplementing a hedgehog 
mutant mouse model with vitamin D was shown to reduce Hh-Gli signaling [56]. 
Hedgehog mutation is very common in basal cell carcinoma [47, 56].  
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Due to the anticipated benefit of vitamin D, current recommendations include 
high dosage supplementation of vitamin D as a part of skin cancer treatment 
regimen[41].  However, the correlation between vitamin D and BCC is not clear due 
to the shortage of mechanistic studies and the inconsistency of the data obtained 
from the epidemiological studies [3, 27]. Interestingly, many epidemiological studies 
question effectiveness of Vitamin D supplementations on BCC treatment including a 
study performed in southeast Michigan[29]. Besides, many practitioners have 
continuously observed ineffectiveness of the Vitamin D supplementation on BCC 
treatment (personal communication).  
On the other hand, Vitamin D is known to be an immune suppressant [61, 62] 
. It was reported that compromising the immune function is associated with 
increasing incidence of NMSC. Organ transplant patients who are taking immune 
suppressant medications have significantly higher risk of developing NMSC [1].  
The purpose of this study is to investigate the sensitivity of BCC tissue to the 
anti-proliferative effect of Vitamin D at the molecular level. Hence, predicting 
possible advantages/disadvantages of vitamin D supplementation for BCC patients. 
Based on our preliminary data, practitioner’s observations, and epidemiological 
studies we hypothesize that the anti-proliferative impact of vitamin D is 
compromised in BCC thus rendering Vitamin D supplementation ineffective and 
potentially detrimental. To test our hypothesis, we will investigate the following aims: 
1. Specific Aim1: To determine Vitamin D metabolism pathway including 
Vitamin D activation genes, Vitamin D receptor (VDR), and VRD co-activator in all 
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specimens from BCC patients (cancer, proximal, Distal tissues) as compared to the 
controls specimens. 
2. Specific Aim2: To determine genes and pathways up/down stream of 
VDR that impact proliferation and/or differentiation in all specimens from BCC 
patients (cancer, proximal, distal tissues) as compared to the controls specimens. 
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Figure 1.1: Vitamin D structure and activation: a) vitamin D3 is formed from 
7-hydroxycholesteril in keratynocytes or obtained from diet. b) calcidiol is the major 
form of vitamin D in blood stream. It is formed from vitamin D3 by hydroxylation, 
mediated by the hepatic enzyme (VD3 25-hydroxylase). c) calcitriol is the active 
hormonal form of vitamin D. it is formed from calcidiol by a second hydroxylation 
reaction mediated by the renal enzyme (25(OH) VD3 1α-hydroxylase). d) Vitamin D 
is inactivated by further hydroxylation the renal enzyme (1α,25(OH)2 VD3 24-
hydroxylase).  
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Figure 1.2: mTOR pathway: The Mammalian Target of Rapamycin protein 
kinase responds to environmental factors, which impact its activity in various ways. 
Manipulation of TOR activity can be initiated through AKT, AMPK, TSC, or inhibition 
through direct binding to mTOR complexes such as rapamycin. mTOR impacts 
important cellular functions and growth through S6K and 4EBP phosphorylation 
which control the translation process.  
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CHAPTER 2: RESEARCH DESIGN AND METHODS  
This case control study is a human study with mechanistic approach. Our 
samples are tissue specimens excised from cases and controls in Henry Ford 
Hospital. Subjects were recruited by dermatology research group after obtaining the 
required protocols approved by Henry ford health system IRB (institutional review 
board).  
Participant Selection: 
Participants are either basal cell carcinoma patients (Cases), or non-cancer 
patients (Controls). Subject’s eligibility for the study was determined according to the 
inclusion and exclusion criteria in the protocol. Approval of the protocol was 
obtained prior to starting the recruitment process.  
BCC Patient Selection (Cases): 
Basal cell carcinoma participants are 20 patients from south east Michigan 
from both genders. Subjects’ age ranges between 46 and 89 years with average 74 
years old. All patients were diagnosed with BCC in the head and nick area. In 
details, locations include nose, ear, cheeks, eye canthus, lips, chin, neck, temple, 
and forehead.  
Inclusion Criteria: For inclusion, the subject must: 
1. Be at least 18 years old at time of participation. 
2. Have a basal-cell carcinoma and accept to have it excised. 
3. Agree to abide by the investigator’s guidelines regarding skin cancer screening; 
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4. Be able to understand the requirements of the study and the risks involved, and to 
sign the informed consent form. 
5. Agree to follow and undergo all study-related procedures (blood sample). 
Exclusion Criteria: Subjects will be excluded if any of the following apply: 
1. Women who are lactating, pregnant, or planning to become pregnant. 
2. Patients with a recent history of serious systemic disease. 
3. Patients with history of intestinal malabsorption, resection, or bypass, which are 
known to affect vitamin D nutrition.                                                                                                      
4. Patients receiving pharmacologic vitamin D replacement (i.e., 50,000 IU/ week or 
more), as well as systemic or topical agents involving vitamin analogs or derivatives 
(such as Dovonex) in the last 4 months. 
5. Patients undergoing PUVA (Psoralen Ultraviolet A) therapy. 
6. Patients using medications known to affect vitamin D metabolism such as 
Dilantin, Phenobarbital, and Cholestyramine. 
7. Patients on immunosuppressive therapy. 
8. Any reason the investigator feels the patient should not participate in the study.  
Control selection:  
Control subjects are six healthy individuals whose age is higher than 50 old. 
Cases and controls are coming from the same population and geographic area of 
south east Michigan. Controls were never diagnosed with skin cancer. All controls 
were scheduled for eye-lifting procedure, and agreed to donate their excised facial 
tissue for this study. This assured comparable location of the skin specimens, and 
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therefore the accessibility of sun light among specimens. All inclusion, exclusion, 
legal documentation, and recruiting procedures were similar for cases and controls 
with the exception of BCC diagnosis. While it is an inclusion criterion for the cases; 
cancer diagnosis is considered an exclusion criterion for the controls. 
Recruitment Process:  
Patients with non-melanoma skin cancer coming to Henry Ford Hospital for 
treatment were the candidates for this study. Medical records of eligible candidates 
were reviewed first to determine if any exclusion criteria applied. Candidates that 
were still eligible after record review were contacted by an investigator, co-
investigator, or collaborative member. Invitations to participate were delivered to 
candidates via mail or phone. Eligible subjects who showed interest in participating 
in this study were scheduled for a screening visit.  
Screening visit:   
The study involved attending Henry Ford outpatient facility for one screening 
visit prior to the actual tumor excision and blood draw appointment. Failure to attend 
the screening visit resulted in exclusion of the subject from study. Many critical 
procedures were performed during this visit. First, authorized members of the study 
team confirmed inclusion and exclusion criteria from the medical record and the 
interview. Also, participant’s skin was examined, typed, and assessed for skin 
cancer risk. Finally, the interviewer provided educational consent to the subject 
about the study, and obtained the required legal permissions. 
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1. Inclusion/Exclusion Criteria determination, Informed Consent and 
HIPAA Authorization: Patients were assessed for inclusion and exclusion criteria. If 
the patient was found eligible to participate in the study, written informed consent 
and written authorization to disclose protected health information under HIPAA 
regulations were obtained from the patient. This was completed prior to performing 
any procedure related to the study by study staff as listed in the IRB application. 
Sufficient time was given to answer subjects’ questions, and patients were not 
forced to participate by any means. 
2. Demographic Information:  Demographic data that were collected at 
the screening visit, including gender, age and skin photo-type. All our participants, 
cases and controls, were Caucasian. BCC patients were 6 males and 14 females. 
Descriptive statistics was performed on age data for cases from both genders. Age 
of patients at time of diagnosis was tested for normal distribution. 
3. Pertinent Medical History and risk factors: At the visit, information 
related to the current or past medical history of skin cancer was obtained. This 
included date of onset, anatomical areas affected, disease course, and result of 
previous biopsies, previous treatments, and treatment responses. Presence of risk 
factors for skin cancer (such as previous history, family history, degree of exposure 
to UV radiation, history of several previous severe sunburns especially in childhood 
and adolescence) was documented. Other relevant information consisting of, but not 
limited to, complete past medical history, including the presence of systemic 
disorders and conditions causing an immune-compromised state would be 
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acknowledged. Also, Interviewer obtained a list of all systemic and topical 
medications taken by the subject at the time recruitment.  
4. Dermatological Examination: A focused dermatologic examination was 
performed for all patients. It included skin photo-typing and skin cancer screening for 
suspicious lesions. All participating cases were diagnosed with basal cell carcinoma 
lesion in the neck and head area. Exact distribution of cancer locations is shown in 
table (2.1). 
Excision of tissue specimens from BCC patients: 
     Dermato-surgeons at Henry Ford Hospital excised tissue specimens from 
the enrolled patients. Specimens were collected from each recruited BCC patient 
from three different locations; the cancer mass itself, normal tissue surrounding the 
cancer and directly adjacent to it (proximal), and normal tissue relatively far from the 
cancer location (distal). Distal location is at least one inch far from the proximal 
(figure 2.2). Proximal tissue was separated from the cancer mass under the 
microscope by a specialized pathologist to avoid contamination of proximal tissue 
with cancer cells. Collected specimens will be snap-frozen in liquid nitrogen 
containers. Tissue specimens were then transported to our lab, and kept in liquid 
nitrogen for further processing and analysis.  
Experimental Procedures: 
1. Gene Expression Analysis: 
a) Tissue processing and total RNA extraction: Snap-frozen tissue 
specimens were kept in liquid nitrogen until the time of processing. Tissue 
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specimens obtained from the same patient (Cancer, proximal and distal) were 
handled and processed at the same time. A piece that weighs approximately 50 mg 
from each tissue specimen (From BCC patients and controls) was used for RNA 
extraction. Frozen tissue was homogenized with 1000 ml of the lysis buffer using the 
polytron homogenizer. RNA was then isolated by RNeasy spin column in 
accordance to the protocol provided with the RNeasy RNA kit (Qiagen, Valencia, 
CA). Extracted RNA was stored at (-80 ℃). 
b) Nucleic acid concentration assessment: Nano-drop 
spectrophotometer technology was used to measure the concentration of RNA and 
cDNA in our experiment. The sample’s absorbance was measurements in sample 
volumes of 1μL, and analyzed by a computer linked to the instrument. The Nucleic 
acid concentration will be calculated by the software. 
c) RNA Gel Electrophoresis: Quality of the isolated RNA was assessed 
using the denaturing agarose gel electrophoresis. 1.5% agarose gel was prepared 
with 10X mops buffer (10 ml) and distilled water (72ml), and then mixed with 18ml of 
formaldehyde and solidified in a gel casket. 25μL of sample buffer and 1μL of 
ethidium bromide were added to 5μL of RNA sample before being loaded on the gel. 
Electrophoresis was run at 150 volt at room temperature for 1 hour. The formed 
bands were visualized under UV light in the Trans-illuminator. This method enables 
both quantitative and qualitative detection of the RNA, as the fluorescence density in 
the bands indicates the quantity.  
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d) cDNA preparation: cDNA was prepared 1μg of RNA. The first strand 
was synthesized by the random primers according to the protocol provided with 
ImProm-II reverse transcriptase system from (Promega, Madison, Wl). cDNA was 
then purified in a Qiaquick spin columns provided with the QIAquick PCR 
Purification Kit in accordance to the provided protocol by the manufacturer (Qiagen, 
Valencia, CA). Nano-drop spectrophotometer technology was also used to quantify 
the concentration of the cDNA preparations before they were stored at -20 ͦ C. 
e) Quantitative Real-Time PCR: Gene expression profile in the cancer, 
proximal, distal tissue from the BCC patients as well as from the controls was 
analyzed using the quantitative real-time PCR assay. The real-time PCR reactions 
were prepared according to the protocol provided with the LightCycler 480 SYBR 
Green I Master kit from (Roche, Mannheim, Germany). The studied genes were 
amplified in a hot-start reaction by performing a pre-incubation step at 95 C̊ for 5 min 
before 40 amplification cycles. Each cycle consisted of 10 seconds at 95 C̊ followed 
by 30 seconds at 60 ̊C with an end point measurement of cyber green fluorescence. 
Dissociation curve was generated in the third step by heating the mixture to 95 ̊C 
for10 seconds followed by cooling down to 60 C̊ for 30 seconds and heating to 95 C̊ 
again for 30 seconds with all points measurements of the dye fluorescence.  
  We analyzed the expression of 17 genes of interest in the collected tissue 
samples. The expression of each gene was studied in all samples, obtained from 
cancer patients (cancer tissue, normal proximal, and normal distal tissue) and from 
controls, in the same 69 multiwall plate to be loaded in the thermo-cycler at the 
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same time. A different set of primers was used in each run. Each set of primers was 
specifically designed to amplify one of the studied genes. Our studied genes are: 
VDR, 1αOHase, 25OHase, 24OHase, RPL13, PARP-1, src, DRIP, P53, Bcl-2, 
Apex-1, VEGF, MDM2, Gli1, Ras, GADD45A, and Caspace-3. In this study, 3 μL of 
template cDNA was added to each reaction of a total volume of 25 μL. Primers for 
VDR, 1αOHase, 25OHase, 24OHase, SRC, DRIP were designed in our lab using 
the (Beacon Designer, PREMIER Biosoft International) program. Gli1and Ras 
primers sequences were taken from articles [51, 55] respectively. Sequences of 
primers used to amplify these genes are shown in table (1). Primer sets that were 
used to study other genes were purchased from (Real time Primers, LLC; Elkins 
Park, PA). They were designed and synthesized by the selling company.  
Protein Expression Analysis: 
a) Protein extraction: Whole cell protein extract was prepared from 100 
mg of the skin tissue using RIPA buffer (Igepal CA-630, sodium deoxycholate, SDS 
0.1%, and 1X PBS) with protease inhibitors added just before use (β-Mercapto-
ethanol 10mM, PMSF 10μg/ml, pepstatin A 1ug/ml, Triton X-100 15μl/ml, Protease 
inhibitor 1X). Skin tissue was first crushed with the buffer manually using porcelain 
mortar and pestle, and then was fully homogenized using the Teflon homogenizer. 
Samples were left on ice before they were centrifuged for 10 minutes at 14000 rcf 
and 4℃. Protein concentration in the supernatant was quantified by performing 
Bradford assay using Protein Assay Kit I (Bio-Rad, Hercules, CA, USA). Whole cell 
extracts were stored in -80 ͦC.  
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b) Western Blot Assay: Protein expression was analyzed by performing 
western blot assay with 100 μg of the whole cell extract. Protein extract was run on 
10% SDS-PAGE gel to perform the western blot assay. Protein bands were 
transferred to a nitro-cellulose membrane, which was then blotted by incubation with 
manufacturer-recommended dilutions of protein- specific primary antisera developed 
against our target protein (s), followed by incubation in secondary anti-body. Bands 
were then incubated in SuperSignal West Pico chemiluminescence substrate 
(Pierce Biotechnology), and visualized and quantified using a Chemimager system 
(AlphaInnotech, San Leandro, CA, USA). Protein quantity was measured as (IDV) of 
the band per microgram of protein. The remaining gel after transfer was stained 
using gel code blue (Pierce Biotechnology) to ensure equal loading and uniform 
transfer. 
 The primary antisera used in this study were specifically against: VDR (D-6, 
Santa Cruz Biotechnology, Santa Cruz, CA, USA), REDD1 (poly Ab, proteintech 
group inc, Chicago, IL, USA), 4E-BP1 (T37/46, Cell Signaling Technology, Beverly, 
MA, USA), VDREBP (hnRNP, Santa Cruz Biotechnology, Santa Cruz, CA, USA), P-
AKT (S473, Cell Signaling Technology, Beverly, MA, USA), P-AKT(T308, Cell 
Signaling Technology,  Beverly, MA, USA). The secondary anti-bodies that were 
used are: Goat-Anti rabbit IgG-HRP linked (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA), and Goat-Anti mouse IgG-HRP linked (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA). Results are shown as integrated density value (IDV) per microgram 
of protein. 
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2. Detection of KRas Mutation: 
a) ASB-PCR Assay: KRas mutation was detected in the tissue samples 
from BCC patients (cancer, proximal, and distal) as well as from controls using the 
ASB-PCR (Allele-Specific PCR with Blocker). The technique was applied as 
described in literature [51]. Each mutant-specific forward primer was designed to 
detect a specific mutant (ras) genotype. Amplification of the wild type sequence is 
prohibited by adding a blocking agent, which is complementary to the wild type 
sequence with a phosphorylated 3` end rendering it un-extendable ( Figure 2.1). 
Mutant allele specific primers and the wild type blocker were designed as forward 
primers. All mutant specific, wild type, and blocker primers were used with the same 
reverse primer. 
b) Primers used in Detecting KRas point mutation in BCC tissue 
specimens: Four different mutant specific primers were used. Each primer was 
designed to detect a different single point mutation, and has the mutated base 
located in the 3’ end of the primer sequence. The mutations that are detected in this 
assay are on the Guanine bases in the locations 215 and 216 of the primer. The 
mutant specific primer 2.1 contains the substitution of G in the location 216 with T. 
Mutant specific primer 4.1 has G 215 substituted with A. Mutant specific primer 5.1 
contains the substitution of G 215 with C. Finally, mutant specific primer 7.1 has G 
216 substituted with C. The blocker is complementary of the wild type, and has the 
wild type form of the mutated bases G 215 and G 216 located in the center of the 
blocker sequence with a phosphorylated 3’ end. The sequences of the primers used 
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in the assay, and the associated mutations detected by each primer are shown in 
Table 2.2. Melting temperatures are also distinct between the mutant specific 
primers and the wild type specific blocker. Melting temperature of the blocker is 
equivalent to the PCR extension temperature, while Tm of the mutant allele specific 
primer is about 10 ℃ below that. The last difference between the two types of 
primers is the concentration used in the reaction. To effectively block the 
amplification of the wild type allele in the PCR reaction, the concentration of the 
blocker should be four times that of the mutant specific primer in the reaction.  
3. Data Analysis and Testing For Statistical Significance: 
Gene expression in all samples was measured as fold increase of the 
controls average. Fold change values for samples from tissue different groups were 
compared to each other. An array of three housekeeping genes (RPL13A, B.actin, 
and GAPDH) was used as an internal control to normalize real-time PCR data. 
B.actin protein level was used as an internal control for all western-blot protein 
analysis assays. ANOVAs analysis was performed between the four specimen 
groups (cancer, proximal, distal, control) to test for significant difference between the 
means, followed by Bonferroni’s multiple comparison’s test between each two 
groups. In all tests, a P value ≤0.05 was considered significant. Fold change values 
were calculated from the real-time (Ct.) Values using the PCR array analysis 
software. Real time data results are illustrated in two forms, column graph 
representing only groups’ averages and SEMs, and scatter plots for individual data 
points. Protein expression analysis is shown in a column graph with averages and 
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SEMs. Individual samples in protein assays were shown in a picture of the western-
blot membrane image. Groups with similar letters in the graphs are not significantly 
different from each other. Pvalue≤0.05 is considered significant. 
Age data for participating BCC patients, was tested for normal distribution 
through Kolmogorov-Smirnov normality test using SPSS software. The number of 
BCC patients in each age group was plotted against the center of its age range; a 
trend-line was drawn using the Microsoft Excel program.  
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Table 2.1: Distribution of BCC locations among participants: All of the 20 
cases recruited in our study were diagnosed with basal cell carcinoma in the head 
and nick area. On the other hand, Normal tissue from the control participants was 
excised during eyelid-left surgery, assuring comparable sun exposure among 
different tissue groups.    
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Cancer Location Number of Cases 
Nose 4 
Cheek 1 
Eye canthus 1 
Ear 3 
Neck 2 
Temple 4 
Forehead 3 
Chin 1 
Lip 1 
Total Cases 20 
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Table 2.2: The Real-Time primers sequences: Real time gene specific 
primers were used to detect the message of the target genes. Sequences of both 
sense and antisense primers used in our study are shown in the table below.  
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Gene Sense Primer Sequence Antisense Primer Sequence 
VDR 5 -́GTCGTCCATGGTGAAGGA-3 ́ 5 -́CCAGTTCGTGTGAATGATGG-3  ́
1αOH 5 -́CCGGGAGAGCTCATACAG-3 ́ 5 -́TGTTTGCATTTGCTCAGA-3 ́ 
25OH 5 -́AGCAAATAGCTTCCAAGG- 3  ́ 5 -́GGCAAGTACCCAGTACGG-3 ́ 
SRC 5 -́ TGAAAGTGGAAAAGAAAGAA 
     CAGATG-3  ́
5 -́GTCAAGGTCAGCTGTAAA 
    CTGGC-3 ́ 
DRIP  5 -́GGAGCATCACAGTGGTAG 
    TCAGG-3 ́ 
5 -́CCGCTTTGGAGGCTTATC 
    TTTGC-3  ́
Gli1 5′-CTCCCGAAGGACAGGTAT 
    GTAAC-3′ 
5′‐CCCTACTCTTTAGGCACT 
    AGAGTTG-3′ 
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Table 2.3: Sequences of the primers used in detection of KRas gain of 
function mutations: ASB-PCR technique was employed in the detection of point 
mutation of KRas oncogene in BCC tissue samples. It involves the usage of Mutant 
allele-specific primers (ASP) accompanied with wild-type allele specific Blocker. 6 
different ASPs were used to detect 6 possible point mutations, with the mutated 
base located at the 3` end of the primer. The wild-type blocker is a primer that 
complements the wild-type sequence with the possibly mutated base located at the 
center of the primer sequence. The blocker has a phosphorylated 3` end to block 
the extension of the wild-type allele.  
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PRIMER SEQUENCE (FP) 
Nucleotide 
Substitution 
 WT                               AAACTTGTGGTAGTTGGAGCTGG   
MUT 2.1                                   TGTGGTAGTTGGAGCTGA G216A 
MUT 4.1                          AACTTGTGGTAGTTGGAGCTA G215A 
MUT 5.1                            ACTTGTGGTAGTTGGAGCTT G215T 
MUT 7.1                                   TGTGGTAGTTGGAGCTGC G216C 
BLOCKER                                                     TTGGAGCTGGTGGCGTAGG-PO4   
REVERSE PRIMER          TGATTCTGAATTAGCTGTATCGTCAA   
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Figure 2.1: Illustration of tissue excision protocol: three tissue specimens 
were excised from each recruited basal cell carcinoma patient. The first specimen is 
the BCC mass itself and is named (Cancer). The second tissue specimen is the 
normal tissue adjacent to the BCC mass and directly surrounding it. This piece of 
tissue was carefully separated from the cancer mass under the microscope by a 
specialized trained pathologist to insure uniformity of the cell type and avoid 
contamination of the tissue specimen with cancer cells. This specimen is named 
(Proximal) to distinguish it from the other normal tissue specimen obtained from the 
same patient. The third specimen is a normal tissue excised from a location that is 
relatively far from the cancer mass, and was named (Distal).    
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Figure 2.3: Illustration of ASB-PCR technique that was used to detect KRas 
point mutation in BCC tissue specimens: Shown example represents KRas mut 5.1 
point mutation, the mutation that was successfully detected in our BCC patients. The 
mutation involves the conversion of G215 to T. a) The (mut 5.1) mutant allele 
specific primer is anchored at the 3` end with the T base that base pairs with the A. 
When the primer is annealed to the mutated sequence in the cDNA, perfect 
matching causes the amplification of the mutant allele. b) The wild-type specific 
blocker is a primer that is complementary to the wild-type allele sequence. 
Therefore, it perfectly base pairs with wild-type allele in the cDNA sample. The 3` 
end of the blocker is phosphorylated rendering the wild-type allele unamplified. C) 
shows the similarity between the wild-type allele primer and the wild-type allele 
blocker.  
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CHAPTER 3: RESULTS AND ANALYSIS 
This case-control study aims to explore Vitamin D metabolism in basal cell 
carcinoma tissue and in normal tissue from both BCC patients and controls. Hence, 
predicting the sensitivity of different tissue groups to the anti-proliferative effect of 
vitamin D. We collected three tissue specimens from each BCC patient; cancer 
tissue, normal tissue proximal to the cancer, and normal tissue distal to the cancer. 
Eyelid tissue from cancer-free subjects was used as a control.  
Analysis of cases and controls demography:  
Cases and controls were recruited in Henry Ford Hospital after the approval 
of our protocol. Twenty BCC patients were recruited in this study. Out of which, 14 
were males and 6 were females. Patients’ ages ranged between 46 and 89 years. 
All patients were diagnosed with BCC in the head and neck area. Controls were 6 
cancer-free individuals whose age was greater than 50 years at the time of 
participation. Cases and controls were from south east Michigan. Controls were pre-
scheduled for eyelid lifting procedure, and have agreed to donate their excised 
tissue for this study. Obtaining all specimens from sun-exposed locations reduces 
the chance that observed differences among tissue groups are related to variations 
in sun exposure. All participants, cases and controls, were Caucasian individuals, 
which eliminated race-related differences. However, all controls were females as no 
male participants could be successfully recruited. 
Analysis of age distribution among BCC patients:  Cases ages at the time of 
diagnoses ranged between (43-89 years old). Their average age was 74 years, and 
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both the mode and the median age were 80 years old. BCC cases age data failed to 
pass the KS normality test indicating that they were not normally distributed around 
the mean age, at least in our sample (Table 3.1).  
To illustrate the abnormal distribution of patients’ age, they were grouped 
based on their ages at time of diagnosis. These groups were ≤45, 46-55, 56-65, 66-
75, 76-85, and 86-90 years old. The number of patients within each age group was 
plotted at the middle age range covered in that group (figure 3.1). The trend line 
indicated that the number of cases diagnosed at each age was increasing gradually 
as the age increase until 75 years of age. A peak in the number of cases was 
formed between 75 and 85 years, followed by a rapid decline after 85 years of age. 
The trend line appears skewed, which is compatible with the result of the normality 
test.  
Total-RNA yield from BCC patients’ tissue specimens:  
Specimens obtained from the same person (cancer, proximal, distal) were 
handled at the same time throughout the process of RNA extraction and purification. 
Cancer tissue showed tendency to yield more RNA concentration than the normal 
tissue from same person. Figure (3.2) shows an image of denaturing RNA gel 
electrophoresis for RNA extracts. The three specimens were taken from the same 
person, at the same time, and had the same weight before processing. In 
agreement with the picture, RNA nano-drop spectrophotometer quantification 
revealed that cancer tissue yielded about 2-2.5 times as much RNA as the normal 
tissue of the same patient. 
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 In order to neutralize this factor and avoid any impact on the accuracy of our 
results, gene expression analysis was normalized to total-RNA quantity. RNA 
extract volumes used for cDNA preparation were adjusted to contain equal amounts 
of RNA (1μg of RNA). Furthermore, cDNA concentrations were quantified once 
more before they were used for gene expression analysis. Finally three 
housekeeping genes (RPL13, GAPDH, and β-actin) were used as internal controls 
to normalize the data using the PCR array analysis program.      
Analysis of the expression of vitamin D metabolism key genes: 
Studying the differences in vitamin D metabolism key genes among tissue 
groups is a main objective of this study. We analyzed the expression of the key 
genes in metabolizing vitamin D 25OHase, 1αOHase and 24OHase genes[63]. 
Quantitative Real-Time was employed for that purpose. cDNA was constructed from 
1μg of purified RNA and was used to quantify the message of the target genes. An 
array of three housekeeping genes (RPL13A, GAPDH, β.actin) was used as an 
internal control to normalize the data using the PCR array analysis software. Real-
Time Ct. values were converted to fold changes of a reference point, which was the 
average Ct. of the control group. Data was analyzed using the one-way ANOVA 
analysis, with subsequent Bonferroni multi group comparison. Groups with similar 
letters were not significantly different from each other. Pvalue˂0.05 was considered 
significant.   
Vitamin D3 25-hydroxylase (CYP27A1) gene expression was analyzed in 
tissue specimens. Gene expression data for VD3 25-OHase is shown in (Figure 3.3) 
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and it suggest that the expression of this gene is significantly down-regulated in the 
cancer tissue comparing to the non-cancerous tissue groups obtained from BCC 
patients as well as from the controls. Both proximal and distal tissue groups are not 
significantly different from each other. Despite the visual elevation of VD3 25-Ohase 
message in the proximal and distal tissue groups comparing to the controls, the 
differences were not statistically significant. 
 25-OH D3 1α-hydroxylase enzyme catalyzed the formation of 1α, 25 (OH)2 
VD3, which is the hormonal form of vitamin D. this enzyme was shown to be 
regulated at the transcription level [64].  Expression analysis of the gene encoding 
this enzyme shows that the message is significantly up-regulated in the cancer and 
the proximal tissue groups. The distal tissue specimens show a tendency to be 
higher than the control group, but without a statistical significance (Figure 3.4). 
Inactivation of the hormonal form of vitamin D3 occurs through a further 
hydroxylation by the catabolism enzyme 1α, 25 (OH) 2 VD3 24-hydroxylase 
(CYP24A1). Our data indicate that this gene is significantly down-regulated in the 
distal tissue group comparing to other tissue groups. Cancer and proximal and 
control tissue groups seem to retain similar message levels of this gene (Figure 3.5). 
Analysis of vitamin D receptor (VDR) and its co-activators:  
Vitamin D exerts its hormonal effect through activating a nuclear receptor 
(VDR) which hetero-dimerizes with RXR. VDR-RXR heterodimer binds to specific 
sequences of the DNA in the promoter region of the target genes called vitamin D 
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response elements. Once that happens, two types of co-activator complexes (SRC 
and DRIP) bind to VDR promoting the transcription initiation of the target gene [59].  
Vitamin D receptor was studied at the gene message level and the protein 
level in all tissue groups. Expression analysis of VDR gene shows that the cancer 
tissue group has a significant up-regulation of VDR gene comparing to both the 
proximal and the control tissue. VDR gene expression in the distal tissue group 
shows tendency to be higher than the control, but lower than the cancer. 
Statistically, the distal tissue group is not significantly different from any other tissue 
group (Figure 3.6). VDR protein analysis in different tissue groups is shown in 
(Figure 3.7). It reveals that VDR protein level in the cancer group is significantly 
higher than other tissue groups. Proximal and distal are not significantly different 
from each other or from the control group. In conclusion, both gene expression and 
protein analysis indicate that BCC tissue contains higher levels of vitamin D 
receptors than the cancer free tissue of the patients. 
SRC is a protein complex that operates as a co-activator of VDR. It binds to 
the receptor subsequent to its binding to the VDRE in the target gene’s promoter. 
SRC possesses a histone-acetylase activity. Chromatin remodeling caused by SRC 
makes the promoter region more accessible to other transcription factors. This 
action is followed by the binding of DRIP complex which recruits components of the 
transcription machinery in place[65]. We assessed the expression of the genes 
encoding SRC and DRIP co-activator in BCC patients and the controls specimens. 
Only the cancer tissue showed significant increase in the expression of SRC as 
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compared to other tissue groups. SRC gene expression in the proximal and the 
distal groups mimic the control group (Figure 3.8). Similarly, DRIP gene expression 
in the cancer tissue was significantly higher than other tissue groups. No significant 
differences were found in DRIP gene expression among proximal, distal, and control 
tissue groups (Figure 3.9).  
Studying the impact of VRD over-expression in BCC on mTOR pathway:  
VDR is known to negatively regulate mTOR through impacting REDD1. The 
latter gene is a VDR target gene that contains VDRE in its promoter. Up-regulation 
of this gene is known to inhibit the activity of mTOR. VDR effect on its target gene 
transcription regulation was shown to be impaired when VDREBP are up-regulated. 
These proteins compete with VDR over the binding sites in the target genes 
promoters [45]. We investigated whether the observed up-regulation of VDR in 
cancer tissue is translated into reduction of mTOR signaling. For that purpose, we 
studied some important proteins upstream and downstream of mTOR.  
VDREBP protein levels analysis in all tissue groups is shown in Figure 3.11. 
Our data shows that VDREBP protein levels are significantly elevated in the cancer 
tissue comparing to the other groups. In contrast, the proximal tissue contains 
significantly lower amounts of this protein than the other groups. The distal and the 
control groups are not normal significantly different from each other. 
REDD1 protein levels (Figure 3.10) reveal that the level of this protein in the 
cancer group is significantly higher than in other tissue groups. The proximal tissue 
tends to have a lower REDD1protein level than the distal and the control groups. 
50 
 
 
 
However, the three groups (proximal, distal, and control) are not significantly 
different from each other. 
mTOR phosphorylates  TIF4E-binding protein (4EBP), impairing its ability to 
bind to TIF4E protein [43]. Level of 4EBP phosphorylation has been used as an 
indicator for mTOR activity. Therefore, P-4EBP protein levels were assessed in 
cancer and normal tissue of BCC patients and compared to the control group 
(Figure 3.12). Results show that p-4EBP levels are significantly elevated in the 
cancer tissue comparing to the control group. On the other hand, the proximal tissue 
contains significantly lower amounts of this protein than the control. The distal tissue 
is not significantly different from the control group.  
Analysis of key genes up-stream of mTOR in (Ras- IP13-AKT-mTOR) pathway: 
IP13-AKT-mTOR is one of the pathways that were reported to be up-
regulated in many cancers[66]. AKT is phosphorylated in two sites (S473 and Th 
308). Both AKT phosphorylation sites are required to up-regulate mTOR activity. 
Ras is an important oncogene upstream of this pathway and is recurrently reported 
to have a gain of function mutation in many types of cancers [49].  
Protein analysis shows that levels of AKT protein that are phosphorylated at 
the location (S473) are significantly elevated in both cancer and proximal tissue. In 
contrast, p-AKT (S473) levels in the distal and the control tissue groups are not 
significantly different from each other (Figure 3.13). P-AKT (Th308) protein levels 
were also detected in our tissue groups. Quantification of the exposed bands 
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indicated that levels of P-AKT phosphorylated at the location (Th308) follows the 
same rend of p-AKT (S473) as shown in Figure 3.14. 
The expression of KRas gene was also assessed in our tissue groups. KRas 
mRNA was quantified using real-time PCR with KRas wild-type allele primers. Our 
data suggest that KRas gene is up-regulated in all tissue groups obtained from BCC 
patients comparing to the control group. However, we noticed that the expression 
decreases as the location of the tissue specimen gets farther from the cancer 
location. Statistically, KRas gene expression in the cancer and the proximal groups 
is significantly higher than the control group but not than the distal tissue. The distal 
tissue group is not significantly different from any other group including the control. 
(Figure 3.15) 
Detection of KRas point mutation in BCC issue samples using the ASB-PCR 
technique: 
Mutant allele specific real-time PCR with blocker ASB-PCR was used to 
detect the presence of point mutations in KRas gene [51]. Specifically designed 
primers were used to detect different possible point mutation that may occur in 
cancer cells. Each mutant allele specific primer was used to detect the presence of 
its corresponding point mutation in our tissue samples. Each ASB-PCR experiment 
was repeated with and without the addition of the wild-type allele specific blocker to 
minimize the non-specific amplification of the wild-type allele.  
Tissue samples were inspected first for the presence of the point mutation 
(mut 2.1) in KRas gene using (mut 2.1) allele specific forward primer(Figure 3.16). 
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Results show that the message obtained using (mut 2.1) primer follows the same 
trend obtained from the wild-type primer. The only significant difference observed 
was in the cancer group in absence of the blocker. Upon adding the wild-type 
specific blocker to the PCR reaction, the previously noted significant increase was 
vanished. Our results suggest that the observed message is a non-specific 
amplification of the wild-type allele, and we concluded that our samples do not have 
(mut 2.1) Kras point mutation.  
KRas point mutation (mut 4.1) was also tested in BCC tissue groups using 
mutant allele specific (mut 4.1) primer. The analysis was performed with and without 
adding the wild-type blocker. The message obtained using (mut 4.1) primer followed 
the same previously described trend, without showing any statistical significant 
among the groups neither with nor without the wild-type blocker. The results suggest 
that the observed message is a non-specific amplification. In conclusion, no Kras 
point mutation was detected by this mutant allele specific primer in our tissue 
specimens (Figure 3.17). 
The third KRas point mutation allele specific primer that was tested with our 
samples was (mut 7.1) primer. The message generated by his primer also followed 
the same trend obtained by the wild-type primer. No statistical significance was 
found among the groups with or without the wild-type specific blocker. This indicated 
that our samples are negative for the mutation detected by his mutant allele specific 
primer (Figure 3.19). 
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Finally, tissue specimens were tested using KRas mutant allele specific (mut 
5.1) primer. The resulting message from this primer without adding the wild-type 
specific blocker follows the same trend as the wild-type primer with no statistical 
significance among tissue groups. Interestingly, upon adding the wild-type allele 
specific blocker to the PCR reaction, all tissue groups from the BCC patients 
(cancer, proximal, and distal) showed significantly higher message levels comparing 
to the control group. Our data suggest the presence of this Kras point mutation in 
cancer, proximal and distal tissue specimens excised from BCC patients (Figure 
3.18). 
Gli1 gene expression analysis as an indicator of Hedge-hog pathway activity:  
Expression of Gli1 gene was quantified in tissue specimens as an indicator of 
Hh-Gli pathway signaling. Our data clearly revealed that cancer tissue has a 
significantly higher expression of Gli1 gene compared to the other groups. This 
result indicates higher activity of Hh-Gli pathway in the cancer tissue, despite the 
higher vitamin D receptor and activation genes in that tissue groups. Proximal and 
distal tissue groups showed Gli1 gene expression that mimics the control group 
(Figure 3.20). 
Analysis of P53-MDM2 pathway: 
P53 is an important tumor suppressor gene in the cell. It is known to be 
regulated through MDM2. Elevated level of p53 protein promotes up-regulation of 
MDM2, which in turn binds and inactivates p53. There is emerging evidence in 
literature suggesting VDR involvement in this regulation [67]. VDR gene was found 
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to contain a p53 response element in its promoter. On the other hand, MDM2 
promoter contains both VDR and P53 response elements [67, 68].  
Expression of P53 gene was quantified and compared among different tissue 
groups. Our data shows that cancer tissue has a significantly higher message of 
P53 gene comparing to all other groups. The Proximal and the distal groups are not 
significantly different from each other or from the control in regards to p53 gene 
expression (Figure 3.21). 
Similarly, MDM2 gene expression analysis (Figure 3.22) proposes that the 
cancer tissue show significantly higher expression comparing to other tissues. 
Proximal and distal groups show slightly lower MDM2 expression than the control 
group, but the differences are not statistically significant. 
Analysis of VEGF gene expression in BCC tissue specimens: 
Vascular endothelial growth factor (VEGF) gene is VDR target gene, and it 
contains VDRE in its promoter [69, 70]. Up-regulation of this protein causes vascular 
growth which triggers angiogenesis around the cancer, which promotes tumor 
growth [70]. 
 Expression Analysis of VEGF gene was carried out in BCC tissue groups as 
well as the control group (Figure 3.23). Our results propose that tissue specimens 
from the cases generally up-regulate VEGF gene comparing to the controls. The 
elevation in VEGF gene expression is statistically significant only in the proximal 
tissue group despite the visual trend of higher message of VEGF in the cancer 
tissue as well.  
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Gene expression analysis of important cell regulators: 
Caspase-3, apoptosis-related cysteine peptidase-3, is a key enzyme in 
controlling the programmed cell death, and it is involved in both intrinsic and 
extrinsic apoptosis pathways[71]. Expression of caspase-3 gene was analyzed in 
BCC tissue groups (Figure 3.25). Data analysis discloses a significant up-regulation 
of caspase-3 gene message in the cancer tissue comparing to all other tissue 
groups. We observed a trend of gradual decrease among the tissue specimens from 
the cases, inferring an inverse relationship between caspase-3 message and the 
distance from the cancer location. In other words, Caspase-3 message in the 
proximal tissue is significantly lower than in the cancer, and significantly higher than 
in the distal tissue. Yet, the proximal and the distal groups are not statistically 
significant from the control group. 
Bcl-2 protein is an anti-apoptotic protein that halts the intrinsic (mitochondrial) 
apoptosis pathway through blocking the release of cytochrome C from the 
mitochondria [72].  Gene expression analysis of our groups proposes a dramatic 
elevation in the Bcl2 message in the cancer tissue comparing to the other groups. 
Proximal and distal tissue specimens are slightly higher than the control, but not 
significantly different from it (Figure 3.24). 
PARP-1 is a chromatin associated protein, and is important for cell survival 
and growth. PARP-1 plays an important role in DNA repair pathways especially the 
BER, and function as a transcription regulator for some genes [73]. The expression 
and the cleavage of PARP-1 were both found to be down-regulated by vitamin D3 
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[34, 69, 73, 74]. The message of PARP-1 gene was quantified in our tissue 
specimens (Figure 3.26). Data clearly reveals that the cancer tissue has significantly 
higher expression of PARP-1 gene comparing to the other tissue groups. Proximal 
and distal tissue has PARP-1 gene expression similar to that in the control group.  
Apex-1 gene expression was also analyzed as another gene involved in DNA 
repair. Our results indicate that Apex-1 gene is significantly down-regulated in the 
proximal and distal comparing to the cancer and the control. Interestingly, the 
expression of this gene in the cancer tissue group mimics that in the control group 
(Figure 3.27).  
Expression analysis of GADD45A gene (growth arrest and DNA-damage-
inducible protein alpha) also indicates higher message in the cancer tissue than all 
other groups. Data analysis discloses a general up-regulation of GADD45A gene in 
all tissue specimens obtained from BCC patients compared to the control. This up-
regulation is greater in the cancer tissue, with a trend of a gradual decline with the 
increasing distance from the cancer. GADD45A message levels in the cancer and 
the proximal tissue are significantly higher than the control. The distal group 
message level falls between the proximal group and the control, but it is not 
significantly different from any of them (Figure 3.28). 
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Table 3.1: Demographic data analysis for BCC Patients: participants are 20 
Caucasian BCC patients from southeast Michigan. Patients are 14 men and 6 
women of age range between (43-89 years old). Average age is 74 years; median 
age and mode are both at 80 years. Ages of men and women are not significantly 
different from each other. Participants’ age data failed to pass the KS normality test.  
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Subjects Ages Males Females All BCC  
Sample size (N) 14 6 20 
Mean age 74.357 74.667 74.45 
Standard deviation (SD) 12.555 11.518 11.949 
 
Std. error of mean(SEM) 3.356 4.944 2.741 
Lower 95% conf. limit 67.109 61.622 68.858 
Upper 95% conf. limit 81.605 87.045 80.042 
 
Minimum age 43 56 43 
Median age (50th percentile) 80 77.5 80 
Maximum age 89 86 89 
 
Normality test KS 0.3163 
Normality test P value 0.0005 
Passed normality test? No 
 
Participants Race All participants are Caucasian 
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Figure 3.1: Ages of BCC patients at time of diagnosis is not normally 
distributed: BCC patients were grouped based on their ages at time of diagnosis. 
Each group covers 10 years within the patient’s age range as the following: ≤45, 46-
55, 56-65, 66-75, 76-85, and 86-90. The number of patients in each group was 
plotted at the middle of group. The trend line shows a peak at (76-85 Y/O) group 
with a gradual increase before 75 Y/o and a sharp decline after 85 Y/o causing the 
skewed distribution.  
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Figure 3.2: RNA integrity gel: denaturing RNA gel electrophoresis image for 
cancer, proximal and distal samples taken from the same patient. Cancer tissue 
yielded 2.5 times as much RNA as the same weight of the normal tissue excised 
from the same person at the same time. Density of the bands is a quantity indicator. 
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Figure 3.3: Vitamin D activation gene Vitamin D3 25-hydroxylase (CYP27A1) 
expression analysis in BCC Patients’ tissue: Data suggests that expression of VD3 
25-OHase is significantly down regulated in basal cell carcinoma tissue comparing 
to normal tissue obtained from BCC patients as well as from the controls. Both 
proximal and distal tissue groups are not significantly different from each other. 
Despite the visual elevation of VD3 25-Ohase message in the normal tissue of the 
patients comparing to the controls, the difference was not statistically significant. 
cDNA was constructed from 1μg of purified RNA and used to quantify the message 
of VD3 25-OHase gene which performs the first step of VD activation yielding 
25(OH)VD3. mRNA was quantified by real-time PCR and expressed as fold change 
of the controls group average. a) Results shown in column representing groups 
averages and SEMs. b) Individual data points presented as scatter plots, error bars 
show the mean and the SEM for each tissue group. Data was analyzed by one-way 
ANOVAs analysis with subsequent Bonferroni’s multi group comparison. Groups 
with similar letters are not significantly different from each other. Pvalue≤0.05 is 
considered significant. 
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Figure 3.4: 25-Hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) 
expression analysis in all tissue groups: cDNA was constructed from 1μg of purified 
RNA and used to quantify the message of the vitamin D activation gene (VD3 1α-
hydroxylase). mRNA was quantified by real-time PCR expressed as fold changes of 
the controls group average. Data shows that the message of VD3 1α-hydroxylase 
which performs the final step of activation of vitamin D and forming the hormonal 
form of it is significantly elevated in both the cancer and the proximal tissue groups 
comparing to the proximal and the control groups. The proximal tissue specimens 
show a clear tendency to be higher than the controls with no statistical significance. 
a) Results shown in column representing groups averages and SEMs. b) Individual 
data points presented as scatter plots, error bars show the mean and the SEM for 
each tissue group. Data was analyzed by one-way ANOVAs analysis with 
subsequent Bonferroni’s multi group comparison. Groups with similar letters are not 
significantly different from each other. Pvalue≤0.05 is considered significant. 
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Figure 3.5: Vitamin D3 catabolism gene 1α, 25 (OH)2 VD3 24-hydroxylase 
(CYP24A1) expression analysis in BCC patients tissue groups: 1μg of purified RNA 
from different tissue specimens were used to construct cDNA, which was in turn 
used to quantify the message of the gene. mRNA of 1α,25(OH)2VD3 24-OHase 
gene was quantified in tissue specimens using real-time PCR and was expressed as 
fold changes of the controls group average. Our data clearly reveals that the distal 
tissue group obtained from BCC patients significantly down-regulates VD3 
catabolism gene comparing to other tissue groups. Cancer tissue itself along with 
the proximal tissue retains normal VD3 catabolism gene activity, showing no 
significant difference from the control group. a) Results shown in column 
representing groups averages and SEMs. b) Individual data points presented as 
scatter plots, error bars show the mean and the SEM for each tissue group. Data 
was analyzed by one-way ANOVAs analysis with subsequent Bonferroni’s multi 
group comparison. Groups with similar letters are not significantly different from 
each other. Pvalue≤0.05 is considered significant. 
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Figure 3.6: Vitamin D receptor (VDR) protein analysis in tissue groups: 
Whole cell extract was prepared using RIPA buffer, and then used to quantify VDR 
protein levels in tissue samples. Western blot was performed by running all groups 
on 10% SDS-PAGE before targeted bands were plotted by specific anti-bodies. 
β.actin protein level was used as an internal control. Quantifying the exposed bands 
reveals that VDR protein level in the cancer group is significantly higher than those 
in other tissue groups. Proximal and distal are not significantly different from each 
other or from the control group. Data was analyzed by one-way ANOVAs analysis 
with subsequent Bonferroni’s multi group comparison. a) Image of the quantified 
western blot bands for VDR and β.actin. b) Results shown in column representing 
the average and the SEM for each tissue group. Groups with similar letters are not 
significantly different from each other. Pvalue≤0.05 is considered significant 
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Figure 3.7: Vitamin D receptor VDR gene expression analysis in tissue 
groups: expression analysis in all tissue groups: cDNA was constructed from 1μg of 
purified RNA and used to quantify the message of vitamin D receptor (VDR) gene. 
mRNA of VDR was quantified by real-time PCR and expressed as fold change of 
the controls group average. Data analysis shows that the cancer tissue group has a 
significant up-regulation of VDR gene comparing to both the proximal and the 
control tissue. In contrast to the proximal tissue, the distal tissue group shows 
tendency to be higher than the normal, but lower than the cancer. The distal tissue 
group is not statistically significantly different from any other tissue group. a) Results 
shown in column representing groups averages and SEMs. b) Individual data points 
presented as scatter plots, error bars show the mean and the SEM for each tissue 
group. Data was analyzed by one-way ANOVAs analysis with subsequent 
Bonferroni’s multi group comparison. Groups with similar letters are not significantly 
different from each other. Pvalue≤0.05 is considered significant. 
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Figure 3.8: Comparison of VDR Co-activator (SRC) gene expression among 
tissue groups: cDNA was constructed from 1μg of purified RNA and used to quantify 
the message of VDR co-activator SRC gene, which was then quantified by real-time 
PCR and expressed as fold change of the controls average. Only the Basal cell 
carcinoma tissue shows significantly elevated expression of SRC comparing to the 
normal tissue from BCC patients and from the controls. Proximal and distal tissue 
groups have normal SRC expression that mimics the control group. a) Results 
shown in column representing groups averages and SEMs. b) Individual data points 
presented as scatter plots, error bars show the mean and the SEM for each tissue 
group. Data was analyzed by one-way ANOVAs analysis with subsequent 
Bonferroni’s multi group comparison. Groups with similar letters are not significantly 
different from each other. Pvalue≤0.05 is considered significant. 
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Figure 3.9: Analysis of DRIP (VDR Co-activator) gene expression among 
tissue groups: 1μg of purified RNA from different tissue specimens were used to 
construct cDNA, which was in turn used to quantify the message of the gene. mRNA 
of VDR co-activator DRIP gene was quantified in tissue specimens using real-time 
PCR and was expressed as fold changes of the controls group average. Our data 
clearly reveals that BCC patients’ cancer tissue shows significantly higher 
expression of DRIP comparing to the normal tissue from BCC patients and from the 
controls. Proximal and distal tissue groups have normal DRIP expression that 
mimics the control group. a) Results shown in column representing groups averages 
and SEMs. b) Individual data points presented as scatter plots, error bars show the 
mean and the SEM for each tissue group. Data was analyzed by one-way ANOVAs 
analysis with subsequent Bonferroni’s multi group comparison. Groups with similar 
letters are not significantly different from each other. Pvalue≤0.05 is considered 
significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
0.5
1
1.5
2
2.5
D
R
IP
 m
R
N
A
 L
ev
el
s 
Fo
ld
 C
h
an
ge
/C
o
n
tr
o
l's
 A
ve
ra
ge
 
Tissue From BCC Patients 
a a 
b 
a 
b) 
a) 
Co
nt
ro
l
Ca
nc
er
Pr
ox
im
al
Di
st
al
0
1
2
3
4
               Tissue from BCC Patients
D
R
IP
 m
R
N
A
 l
e
v
e
ls
F
o
ld
 C
h
a
n
g
e
/C
o
n
tr
o
l'
s 
a
v
e
ra
g
e
77 
 
 
 
Figure 3.10: Protein Levels of vitamin D response element binding protein 
VDREBP: Whole cell extract was prepared using RIPA buffer, and then used to 
quantify VDREBP protein levels in tissue samples. Western blot was performed by 
running all groups on 10% SDS-PAGE before targeted bands were plotted by 
specific anti-bodies. β.actin protein level was used as an internal control. Results 
show that VDREBP protein levels are significantly elevated in the basal cell 
carcinoma tissue. In contrast to the cancer tissue, the normal tissue proximal to the 
cancer location contains extremely low amounts of this protein. The normal tissue 
that is distal to the cancer shows normal levels of this protein that is not significantly 
different from the control group. Data was analyzed by one-way ANOVAs analysis 
with subsequent Bonferroni’s multi group comparison. a) Image of the quantified 
western blot bands for VDREBP and β.actin. b) Results shown in column 
representing the average and the SEM for each tissue group. Groups with similar 
letters are not significantly different from each other. Pvalue≤0.05 is considered 
significant 
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Figure 3.11: Assessment of REDD1 (mTOR blocker) protein levels in BCC 
patients’ tissue: Whole cell extract was prepared using RIPA buffer, and then used 
to quantify REDD1 protein levels in tissue samples. Western blot was performed by 
running all groups on 10% SDS-PAGE before targeted bands were plotted by 
specific anti-bodies. β.actin protein level was used as an internal control. Quantifying 
the exposed bands reveals that REDD1 protein level in the cancer group is 
significantly higher than those in other tissue groups. Proximal tissue group shows a 
visible trend to have lower protein levels of REDD1 than the distal and the control 
groups. However, statistical analysis did not confirm any significant differences 
between the normal tissue from BCC patients and the controls. Data was analyzed 
by one-way ANOVAs analysis with subsequent Bonferroni’s multi group comparison. 
β.actin protein level was used as an internal control. . a) Image of the quantified 
western blot bands for REDD1 and β.actin. b) Results shown in column representing 
the average and the SEM for each tissue group. Groups with similar letters are not 
significantly different from each other. Pvalue≤0.05 is considered significant 
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Figure 3.12:  Assessment of p-4EBP Protein Levels in cancer and normal 
tissue of BCC patients as compared to the controls: Whole cell extract was prepared 
using RIPA buffer, and then used to quantify p-4EBP protein levels in tissue 
samples. Western blot was performed by running all groups on 10% SDS-PAGE 
before targeted bands were plotted by specific anti-bodies.  β.actin protein level was 
used as an internal control. Results show that p-4EBP protein levels are significantly 
elevated in the cancer tissue comparing to the control group. On the other hand, the 
normal tissue obtained from BCC patients that is proximal to the cancer location 
contains extremely low amounts of this protein. The normal tissue that is distal to the 
cancer shows normal levels of this protein that is not significantly different from the 
control group. Data was analyzed by one-way ANOVAs analysis with subsequent 
Bonferroni’s multi group comparison. a) Image of the quantified western blot bands 
for p-4EBP and β.actin. b) Results shown in column representing the average and 
the SEM for each tissue group. Groups with similar letters are not significantly 
different from each other. Pvalue≤0.05 is considered significant 
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Figure 3.13: p-AKT (S473) protein analysis in all tissue groups: Whole cell 
extract was prepared using RIPA buffer, and then used to quantify p-AKT (S473) 
protein levels in different tissue samples. Western blot was performed by running all 
groups on 10% SDS-PAGE before targeted bands were plotted by specific anti-
bodies. β.actin protein level was used as an internal control.  Protein analysis on 
tissue specimens obtained from BCC patients shows that levels of AKT protein 
phosphorylated at the location (S473) are significantly elevated in both cancer tissue 
and normal tissue adjacent to the cancer as compared to the control group. In 
contrast, p-AKT (S473) levels in the normal distal tissue from BCC patients and the 
normal tissue obtained from the controls are not significantly different from each 
other. Data was analyzed by one-way ANOVAs analysis with subsequent 
Bonferroni’s multi group comparison. a) Image of the quantified western blot bands 
for p-AKT(S473) and β.actin. b) Results shown in column representing the average 
and the SEM for each tissue group. Groups with similar letters are not significantly 
different from each other. Pvalue≤0.05 is considered significant 
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Figure 3.14: p-AKT (Th308) protein levels in BCC tissue groups and the 
control group: Whole cell extract was prepared using RIPA buffer, and then used to 
quantify p-AKT (Th308) protein levels in tissue specimens. Western blot was 
performed by running all groups on 10% SDS-PAGE before targeted bands were 
plotted by specific anti-bodies. β.actin protein level was used as an internal control. 
Quantification of the exposed bands indicates that levels of AKT protein 
phosphorylated at the location (Th308) follows the same rend of p-AKT (S473). 
Statistical analysis of the data suggests that levels of p-AKT (Th308) are significantly 
elevated in cancer tissue and proximal normal tissue comparing to the controls. In 
contrast, levels of this protein in the normal distal tissue and the control group are 
not significantly different from each other. Data was analyzed by one-way ANOVAs 
analysis with subsequent Bonferroni’s multi group comparison. a) Image of the 
quantified western blot bands for p-AKT (Th308) and β.actin. b) Results shown in 
column representing the average and the SEM for each tissue group. Groups with 
similar letters are not significantly different from each other. Pvalue≤0.05 is 
considered significant 
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Figure 3.15: KRas wild type gene expression in different tissue groups: 
cDNA was constructed from 1μg of purified RNA and used to quantify the message 
of vitamin D receptor KRas gene. mRNA was quantified using real-time PCR assay 
with KRas wild-type allele primers, and results were expressed as fold changes of 
the controls group average. Analysis of the wild-type KRas gene expression reveals 
that KRas is up-regulated in all tissue groups obtained from BCC patients. The 
observed elevation gradually decreases in relation to the distance of the tissue 
specimen from the cancer. Statistically, KRas expression is significantly higher in 
cancer and proximal tissue groups than the control group but not than the distal 
tissue. The later tissue group is not statistically significantly different from any other 
group including the control. a) Results shown in column representing groups 
averages and SEMs. b) Individual data points presented as scatter plots, error bars 
show the mean and the SEM for each tissue group. Data was analyzed by one-way 
ANOVAs analysis with subsequent Bonferroni’s multi group comparison. Groups 
with similar letters are not significantly different from each other. Pvalue≤0.05 is 
considered significant. 
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Figure 3.16: Detection of (mut 2.1) KRas point mutation in BCC tissue 
groups: mutant allele specific real-time PCR with/without blocker was used to 
detect the presence of (mut 2.1) mutation in all tissue groups. cDNA was 
constructed from 1μg of purified RNA and used to quantify the message of KRas 
mutation using allele specific (mut 2.1) PCR forward primer and the wild-type 
reverse primer. The analysis was performed for each tissue group with and 
without adding wild-type allele blocker to the PCR reaction for comparison. 
mRNA was quantified expressed as fold change of the controls group average. 
Results shows that the message obtained using (mut 2.1) primer follows the 
same trend obtained by the wild-type primer with the absence of the significance 
except for the cancer group which shows significant increase in the message 
level without using the wild type blocker. Upon adding the wild-type allele blocker 
to the PCR reaction the previously mentioned significance disappeared 
suggesting that the observed message is non-specific amplification of the wild-
type allele and no (mut 2.1) KRas point mutation was detected in BCC tissue 
specimens. a) Results shown in column representing groups averages and 
SEMs. b) Individual data points presented as scatter plots, error bars show the 
mean and the SEM for each tissue group. Data was analyzed by one-way 
ANOVAs analysis with subsequent Bonferroni’s multi group comparison. Groups 
with similar letters are not significantly different from each other. Pvalue≤0.05 is 
considered significant. 
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Figure 3.17: Detection of (mut 4.1) KRas point mutation in BCC tissue 
groups: mutant allele specific real-time PCR with/without blocker was used to 
detect the presence of (mut 4.1) mutation in all tissue groups. cDNA was 
constructed from 1μg of purified RNA and used to quantify the message of KRas 
mutation using allele specific (mut 4.1) PCR forward primer and the wild-type 
reverse primer. The analysis was performed for each tissue group with and 
without adding wild-type allele blocker to the PCR reaction for comparison. 
mRNA was quantified expressed as fold change of the controls group average. 
The message obtained using (mut 4.1) primer follows the same trend obtained 
the wild-type primer without showing any statistical significant among the groups 
neither with nor without the wild-type specific blocker. The results suggest that 
the observed message is non-specific amplification of the wild-type allele and no 
(mut 4.1) KRas point mutation was detected in BCC tissue specimens. a) Results 
shown in column representing groups averages and SEMs. b) Individual data 
points presented as scatter plots, error bars show the mean and the SEM for 
each tissue group. Data was analyzed by one-way ANOVAs analysis with 
subsequent Bonferroni’s multi group comparison. Groups with similar letters are 
not significantly different from each other. Pvalue≤0.05 is considered significant. 
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Figure 3.18: Detection of (mut 7.1) KRas point mutation in BCC tissue 
groups: mutant allele specific real-time PCR with/without blocker was used to 
detect the presence of (mut 7.1) mutation in all tissue groups. cDNA was 
constructed from 1μg of purified RNA and used to quantify the message of KRas 
mutation using allele specific (mut 7.1) PCR forward primer and the wild-type 
reverse primer. The analysis was performed for each tissue group with and 
without adding wild-type allele blocker to the PCR reaction for comparison. 
mRNA was quantified expressed as fold change of the controls group average. 
The message obtained using (mut 7.1) primer follows the same trend obtained by 
the wild-type primer without showing any statistical significant among the groups 
neither with nor without the wild-type specific blocker. The results suggest that 
the observed message is non-specific amplification of the wild-type allele and no 
(mut 7.1) KRas point mutation was detected in BCC tissue specimens. a) Results 
shown in column representing groups averages and SEMs. b) Individual data 
points presented as scatter plots, error bars show the mean and the SEM for 
each tissue group. Data was analyzed by one-way ANOVAs analysis with 
subsequent Bonferroni’s multi group comparison. Groups with similar letters are 
not significantly different from each other. Pvalue≤0.05 is considered significant. 
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Figure 3.19: Detection of (mut 5.1) KRas point mutation in BCC tissue 
groups: mutant allele specific real-time PCR with/without blocker was used to 
detect the presence of (mut 5.1) mutation in all tissue groups. cDNA was 
constructed from 1μg of purified RNA and used to quantify the message of KRas 
mutation using allele specific (mut 5.1) PCR forward primer and the wild-type 
reverse primer. The analysis was performed for each tissue group with and 
without adding wild-type allele blocker to the PCR reaction for comparison. 
mRNA was quantified expressed as fold change of the controls group average. 
The message obtained using (mut 5.1) primer without wild-type specific blocker 
follows the same trend as the wild-type primer with no statistical significance 
among the tissue groups. Upon adding the wt. blocker to the PCR reaction, all 
tissue groups of the BCC patients show significant increase in the message of 
(mut 5.1) mutant allele comparing to the control group. Results suggest the 
presence of KRas point mutation (mut 5.1) in cancer, proximal and distal tissue 
specimens excised from BCC patients. a) Results shown in column representing 
groups averages and SEMs. b) Individual data points presented as scatter plots, 
error bars show the mean and the SEM for each tissue group. Data was 
analyzed by one-way ANOVAs analysis with subsequent Bonferroni’s multi group 
comparison. Groups with similar letters are not significantly different from each 
other. Pvalue≤0.05 is considered significant. 
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Figure 3.20: Analysis of Gli1 gene expression among tissue groups: 1μg of 
purified RNA from different tissue specimens were used to construct cDNA, which 
was in turn used to quantify the message of the gene. mRNA of Gli1 gene was 
quantified in tissue specimens using real-time PCR and was expressed as fold 
changes of the controls group average. Our data clearly reveals that BCC patients’ 
cancer tissue shows significantly higher expression of Gli1 comparing to the normal 
tissue from BCC patients and from the controls indicating higher activity of hedge-
hog pathway in the cancer tissue. Proximal and distal tissue groups have normal 
Gli1 expression that mimics the control group. a) Results shown in column 
representing groups averages and SEMs. b) Individual data points presented as 
scatter plots, error bars show the mean and the SEM for each tissue group. Data 
was analyzed by one-way ANOVAs analysis with subsequent Bonferroni’s multi 
group comparison. Groups with similar letters are not significantly different from 
each other. Pvalue≤0.05 is considered significant. 
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Figure 3.21: Expression Analysis of tumor suppressor gene P53 in BCC 
tissue groups: mRNA of P53 gene was quantified in tissue specimens using real-
time PCR. 1μg of purified RNA from different tissue specimens were used to 
construct cDNA, which was in turn used to quantify the message of the gene. Data 
was expressed as fold changes of the controls group average. Our data clearly 
reveals that BCC patients’ cancer tissue shows significantly higher expression of 
P53 comparing to the normal tissue from BCC patients as well as to the controls. 
Proximal and distal tissue groups have P53 expression is not significantly different 
from the control tissue group. a) Results shown in column representing groups 
averages and SEMs. b) Individual data points presented as scatter plots, error bars 
show the mean and the SEM for each tissue group. Data was analyzed by one-way 
ANOVAs analysis with subsequent Bonferroni’s multi group comparison. Groups 
with similar letters are not significantly different from each other. Pvalue≤0.05 is 
considered significant. 
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Figure 3.22: MDM2 gene expression Analysis in experimental tissue groups: 
mRNA of MDM2 gene was quantified in tissue specimens using real-time PCR. 1μg 
of purified RNA from different tissue specimens were used to construct cDNA, which 
was used to quantify the message of the gene. Data was expressed as fold changes 
of the controls group average. Results analysis proposes that basal cell carcinoma 
tissue obtained from our cases show significantly higher expression of MDM2 
comparing to the normal tissue from BCC patients as well as to the controls. 
Proximal and distal tissue groups show a slight decrease in MDM2 expression but it 
is not statistically significantly from the control group. a) Results shown in column 
representing groups averages and SEMs. b) Individual data points presented as 
scatter plots, error bars show the mean and the SEM for each tissue group. Data 
was analyzed by one-way ANOVAs analysis with subsequent Bonferroni’s multi 
group comparison. Groups with similar letters are not significantly different from 
each other. Pvalue≤0.05 is considered significant. 
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Figure 3.23:  Vascular endothelial growth factor (VEGF) gene expression 
Analysis in BCC tissue groups: mRNA of VEGF gene was quantified in tissue 
specimens using real-time PCR. cDNA was constructed from 1μg of purified RNA 
from different tissue specimens, and was used to quantify the message of the gene. 
Data was expressed as fold changes of the controls group average. Results 
propose that basal cell carcinoma tissue obtained from our cases show up-
regulation of VEGF gene expression comparing to the controls. The elevation in 
VEGF expression is statistically significant only in the proximal tissue group despite 
the visual trend of higher message of VEGF in the cancer tissue group a) Results 
shown in column representing group’s averages and SEMs. b) Individual data points 
presented as scatter plots, error bars show the mean and the SEM for each tissue 
group. Data was analyzed by one-way ANOVAs analysis with subsequent 
Bonferroni’s multi group comparison. Groups with similar letters are not significantly 
different from each other. Pvalue≤0.05 is considered significant. 
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Figure 3.24: Gene expression analysis of caspase 3, apoptosis-related 
cysteine peptidase in BCC tissue groups: cDNA was constructed from 1μg of 
purified RNA and used to quantify the message of caspase-3 gene. mRNA of 
caspase-3 was quantified by real-time PCR and expressed as fold change of the 
controls group average. Data analysis discloses a significant up-regulation of 
caspase-3 gene message level in the cancer tissue comparing to all other tissue 
groups. A trend of gradual decrease was observed in the normal tissue of the 
patients in relation to the distance of the specimen from the cancer location. 
Caspase-3 message level in the proximal tissue is significantly lower than in the 
cancer, and the level in the distal tissue is significantly lower than in the proximal. 
Despite the significant difference between the proximal and the distal groups, 
they both are not statistically significant from the control group. a) Results shown 
in column representing groups averages and SEMs. b) Individual data points 
presented as scatter plots, error bars show the mean and the SEM for each 
tissue group. Data was analyzed by one-way ANOVAs analysis with subsequent 
Bonferroni’s multi group comparison. Groups with similar letters are not 
significantly different from each other. Pvalue≤0.05 is considered significant. 
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Figure 3.25: Expression analysis of the anti-apoptotic gene Bcl2 in BCC 
tissue groups: cDNA was constructed from 1μg of purified RNA and used to 
quantify the message of Bcl2 gene. mRNA of VDR was quantified by real-time 
PCR and expressed as fold change of the controls group average. Data 
proposes a dramatic elevation in the anti-apoptotic gene Bcl2 message level in 
the cancer tissue comparing to all other tissue groups. The normal tissue excised 
from BCC patients is slightly higher, but not statistically significant, than the 
control tissue. a) Results shown in column representing groups averages and 
SEMs. b) Individual data points presented as scatter plots, error bars show the 
mean and the SEM for each tissue group. Data was analyzed by one-way 
ANOVAs analysis with subsequent Bonferroni’s multi group comparison. Groups 
with similar letters are not significantly different from each other. Pvalue≤0.05 is 
considered significant. 
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Figure 3.26: Expression analysis PARP-1 gene in BCC tissue groups: 1μg of 
purified RNA from different tissue specimens were used to construct cDNA, which 
was in turn used to quantify the message of the gene. mRNA of PARP-1 gene was 
quantified in tissue specimens using real-time PCR and was expressed as fold 
changes of the controls group average. Our data clearly reveals that BCC patients’ 
cancer tissue shows significantly higher expression of PARP-1 comparing to the 
normal tissue from BCC patients and from the controls indicating higher DNA repair 
activity in the cancer tissue. Proximal and distal tissue groups have normal PARP-1 
expression that mimics the control group. a) Results shown in column representing 
groups averages and SEMs. b) Individual data points presented as scatter plots, 
error bars show the mean and the SEM for each tissue group. Data was analyzed 
by one-way ANOVAs analysis with subsequent Bonferroni’s multi group comparison. 
Groups with similar letters are not significantly different from each other. 
Pvalue≤0.05 is considered significant. 
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Figure 3.27: Apex-1 gene expression analysis in BCC tissue groups: 
Expression analysis Apex-1 gene in was measure using Real-time PCR. 1μg of 
purified RNA from different tissue specimens were used to construct cDNA, which 
was in turn used to quantify the message of the gene. mRNA of Apex-1 gene was 
quantified expressed as fold changes of the controls group average. Data clearly 
shows that Apex-1 gene is significantly down-regulated in normal tissue obtained 
from BCC patients. The expression of this gene is, interestingly, equally reduced in 
the proximal and distal locations. Cancer tissue itself maintains normal expression of 
this gene as the message levels in the cancer group mimic those of the controls. a) 
Results shown in column representing groups averages and SEMs. b) Individual 
data points presented as scatter plots, error bars show the mean and the SEM for 
each tissue group. Data was analyzed by one-way ANOVAs analysis with 
subsequent Bonferroni’s multi group comparison. Groups with similar letters are not 
significantly different from each other. Pvalue≤0.05 is considered significant. 
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Figure 3.28: Expression analysis of the growth arrest and DNA-damage-
inducible protein alpha GADD45A: cDNA was constructed from 1μg of purified 
RNA and used to quantify the message of GADD45A gene. mRNA was 
quantified by real-time PCR and expressed as fold change of the controls group 
average. Data analysis discloses a general up-regulation of GADD45A gene 
message level in BCC patients’ tissue groups comparing to the controls.  The up-
regulation is the greatest in the cancer tissue group with a trend of gradual 
decline in the message level in the tissue with the increasing distance from the 
cancer. GADD45A message level in the cancer and the proximal tissue is 
significantly higher than the control. The distal group message level falls between 
the proximal and control making it statistically not significantly different from any 
of the two groups. a) Results shown in column representing groups averages and 
SEMs. b) Individual data points presented as scatter plots, error bars show the 
mean and the SEM for each tissue group. Data was analyzed by one-way 
ANOVAs analysis with subsequent Bonferroni’s multi group comparison. Groups 
with similar letters are not significantly different from each other. Pvalue≤0.05 is 
considered significant. 
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CHAPTER 4: DISCUSSION AND CONCLUSION 
The relation between Vitamin D status and the onset and progression of non-
melanoma skin cancer-NMSC is not clear. Most of the published human studies 
about vitamin D and NMSC are epidemiological, correlational, and controversial; 
thus they do not address causality. For example, some studies showed beneficial 
influence of vitamin D supplementation on onset and progression of NMSC while 
others suggested adverse impact of vitamin D, and sometimes lack of association 
was concluded [28, 29, 32]. 
Mechanistic studies on BCC are few, and mostly performed using cell-lines or 
animal models. These approaches give rise to problems related to generalizing the 
findings to other experimental models. This study is unique for its mechanistic 
approach while using human tissues taken from NMSC patients and control 
individuals. Also, comparing three groups of normal tissue- proximal, distal, and 
control- is a novel approach.   
Cases and controls were recruited in Henry Ford Hospital after obtaining the 
required approvals. Cases are 20 basal cell carcinoma patients from south east 
Michigan, controls are 6 individuals who were never diagnosed with cancer from the 
same geographic area. This reduces the differences between the two groups in 
exposure to environmental factors. Cases are 14 Caucasian males and 6 Caucasian 
females, and their age ranges between 46 and 89 years with average age of 74. 
Cases are 6 women who were pre-scheduled for eyelid-lift surgery, and age more 
than 50 years. Age of the control subjects ranges between 50 and 69. Ages of the 
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cases and controls are not an exact match, but it was the closest we could achieve. 
Unfortunately, our group could not successfully recruit male subjects among the 
controls despite the attempts. All patients were diagnosed with BCC in the head and 
nick area. Therefore, all cases and controls specimens were excised from locations 
that are exposed to sun. Also, With the exception of BCC diagnoses, all inclusion 
and exclusion criteria were similarly applied in recruiting both cases and controls. 
Interestingly, while the race of the subjects were not pre-determined. However, this 
was an advantage design as it eliminated variations among participants due to race 
differences. 
The trend line for age distribution at time of diagnosis shows gradual increase 
of number of cases diagnosed with the increasing age after 55 years of age, and 
rapid decline after 85 years of age. About 50% of the cases are between 75-85 
years old. We suggest that this can be partially due to the drop in the population 
after that age. The skewed peak is harmonious with the result of the normality test. 
KS test result suggested that age data is not normally distributed.  
Upon isolating total RNA from tissue samples, we observed higher yield of 
RNA per milligram of tissue from the cancer tissue comparing to normal tissue from 
BCC patients as well as tissue from controls. This can possibly be related to the 
histology of BCC tissue. This type of cancer cells has hyper-chromatic nucleus 
surrounded by a small amount of cytoplasm [11] implying higher activity in the 
nucleus and larger proportion of nuclei to the cell volume.  
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To understand metabolism of vitamin D in BCC tumors and normal tissue 
from cases as well as from control subjects, we analyzed the expression of the key 
genes in vitamin D metabolism. The first step of activating Vitamin D3 precursors is 
carried out by VD3 25-hydroxylase (CYP27A1) forming 25(OH) VD3, which is the 
main form of vitamin D in the body [75]. The hormonal form of vitamin D is 1α, 25 
(OH) 2 VD3, and its formation is catalyzed by 25-Hydroxyvitamin D3 1-alpha-
hydroxylase (CYP27B1) gene. 25(OH) VD3 1α-OHase is considered a renal 
enzyme, but it is also expressed in other tissues including keratinocytes [26].  
Interestingly, in cancer tissue, the expression of VD3 25-hydroxylase is 
significantly down regulated, while VD3 1α-OHase, which performs the final step of 
activation, is over expressed. Cells adjacent to the cancer up regulate both 
activation enzymes. Distal tissue shows significant increases only in VD3 25-OHase 
expression. Over expression of VD3 1α-OHase in and around the cancer location is 
not a surprising. This gene was shown to be up regulated in keratinocytes by factors 
like TNF-α and INF-γ even in conditions other than cancer [76]. We propose the that 
normal tissue of the BCC patients increases the local availability of 1α-OHase 
substrate , while the cancer tissue and its feeding cells increase the activation of the 
hormonal vitamin D. Studies have provided evidence that 1α-OHase is 
transcriptionally regulated. For instance, MCF-7 cells overexpressing 1α-OHase 
gene could locally activate vitamin D analogs and exert the transcription effect of 
VDR [26]. Besides, others have demonstrated that renal 1α-OHase is being 
regulated by different positive and negative regulators at the transcription level[64].  
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Further hydroxylation by the catabolism enzyme VD3 24-hydroxylase 
(CYP24A1) inactivates VD3 [39, 77]. Analyses of this gene suggest that distal tissue 
maintains lower expression of this enzyme as compared to other tissue groups.  
Ligand-bound VDR, is a transcription factor that regulates the transcription of 
several target genes [59, 78]. Upon hetero-dimer zing with RXR[65], VDR binds to 
vitamin D responsive elements VDRE region in the target gene’s promoter [79, 80]. 
Sequentially, two types of co-activator complexes (SRC then DRIP) bind to VDR 
and facilitate the transcription initiation of the target gene [59]. SRC, due to its 
histone acyl-transferase activity [81],  makes the promoter region more accessible to 
other factors [65]. Consecutively, DRIP complex binds and recruits the transcription 
machinery components [60, 65]. Cancer tissue significantly over-expresses VDR at 
the message and the protein levels, coupled with higher gene expression of both co-
activators comparing to other tissue groups. 
Our results suggest higher activation of Vitamin D and VDR in BCC tissue 
comparing to other tissue groups. According to literature, this may be advantageous 
for the patient as it can possibly negatively impact the cancer growth. Vitamin D has 
been anticipated to regulate proliferative and differentiating of keratinocytes. This 
idea gave rise to the belief that vitamin D supplementation may be beneficial for skin 
cancer patients [65, 82, 83].  
Some possible mechanism by which vitamin D may exert its anti-proliferative 
effect were assessed in tissue samples. The main objective was to investigate 
whether our findings are associated with the anticipated impact on BCC tissue. VDR 
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is known to negatively regulate mTOR signaling pathway through REDD1. The gene 
encoding REDD1 is a VDR target gene [45]. up-regulating this protein promotes the 
activation of TSC1/2 complexes, which in turn inhibits Rheb resulting in suppression 
of mTOR activity [47]. VDR effect on its target gene was shown to be impaired when 
VDREBP are up-regulated as they compete with VDR over the binding sites on the 
responsive elements [45]. P-4EBP and p-S6K proteins can be used as indicators of 
mTOR activity [48] . Despite the elevated level of VDREBP protein in the cancer 
tissue, Protein analysis shows that REDD1 is significantly up-regulated in that tissue 
group. However, P-4ebp is also significantly high in that tissue group as compared 
to other groups. This interestingly suggests that the expected negative regulation to 
mTOR signaling by VDR through REDD1 is compromised in the cancer tissue.  
Up-stream of TSC1/2 complex, protein analysis shows that the levels of 
phosphorylated AKT, in both S473 and Th308 locations, are significantly elevated in 
cancer and proximal tissue comparing to the controls. Active AKT is known to block 
the assembly and activation of TSC1/2 complex which opposes with the effect of 
VDR.  
Ras gain of function mutation result mainly in up-regulating two pathways, 
PI3K-AKT-mTOR and Ras-Raf-MEK-ERK pathways [50]. KRas point mutation is 
common, and it was implicated  with many types of cancers including colon, skin, 
and breast cancers [51]. Over expression of KRas gene in all tissue groups of the 
BCC patients comparing to the control was concluded from gene expression 
analysis. This can possibly result from a gain of function mutation of this gene.  
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The presence of a KRas point mutation in BCC tissue specimens was 
investigated using ASB-PCR. Among the tested point mutations, only KRas (mut 
5.1) Gain of function mutation was successfully detected in our BCC patients 
specimens. This mutation was surprisingly detected in all tissue groups from the 
cases including the non-cancerous tissue (proximal and distal). In our assay the 
(mut 5.1) mutant allele specific primer is anchored at the 3` end with the T base, 
which base pairs with the discriminating base in the mutant allele. When the primer 
is annealed to the mutated sequence in the cDNA, perfect matching causes the 
amplification of the mutant allele. The wild-type specific blocker is a primer that is 
complementary of the wild-type allele sequence. Therefore, it perfectly base pairs 
with wild-type allele in the cDNA sample. The 3` end of the blocker is 
phosphorylated rendering the wild-type allele unamplified.  
We suggest that the lost mTOR regulation by VDR is possibly related to the 
presence of KRas gain of function mutation. It is possible that the mutation results in 
over activation of Ras-PI3K-AKT-mTOR signaling pathway, and hence, overcome 
the inhibition effect of vitamin D. However, confirmation of KRas mutation causality 
in eliminating vitamin D regulation of mTOR needs further investigation. Up-
regulation of PI3K-AKT-mTOR pathway was reported in other cancers such as 
breast cancer, and it was shown to alter the cancer’s response to endocrine 
treatments [48, 49].  
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Hedge-hog mutation is characteristic of BCC resulting in excessive signaling 
of the pathway [46]. Over expression of Hh-Gli pathway, results in modifying the Gli 
code, which affects tumor progression and recurrence [53, 56]. Interestingly, Vitamin 
D has the ability to inhibit Hh-Gli pathway and alter the Gli code to promote 
differentiation [46, 53]. PTCH was found to block SMO through vitamin D3 and its 
derivatives [9, 56]. Studies have shown that providing the active form of vitamin D to 
PTCH mutant mouse model reduced Hh-Gli signaling and reduced the incidence of 
spontaneous skin cancer in that model [9, 56]. In addition to the direct impact of 
calcitriol, VDR seems to have a role in regulating Hh-Gli signaling [9, 46]. Knocking 
out VDR resulted in Hh protein ligand over expression, and hence up regulated Hh-
Gli signaling [9]. Vitamin D supplementation was projected to be beneficial for 
prevention and treatment of skin cancer [84].  
Despite the up-regulation of both vitamin D activation gene 1α-OHase and 
VDR in cancer tissue specimens, Gli 1 gene is significantly overexpressed in that 
tissue group. The expected impact of higher activation of vitamin D and its receptor 
on inhibiting Hh-Gli signaling was not observed in our tissue samples. Other 
investigators revealed a cross talk between mTOR/S6K1 pathway and Hh-Gli 
pathway. Their results suggest that up regulation of mTOR pathway can cause SMO 
independent activation of Gli1 [85]. Therefore, we expect that the up regulation of 
mTOR pathway that we have observed in BCC samples may contribute to Gli1. 
Concomitantly, we propose that the up regulation of mTOR in our BCC samples 
opposes the effect of vitamin D on Hh-Gl1 signaling. Both vitamin D and VDR 
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impact PTCH capacity to block SMO, while mTOR/S6K1 up-regulates Gli1 
downstream of SMO [57, 85].  
Up regulation of Hh-Gli pathway was shown to overexpress the anti-apoptotic 
gene Bcl2, and Gli2 protein seems to be responsible for that [52]. This is compatible 
with our results that show significant over expression of Bcl2 in the cancer tissue. 
On the other hand, other publications reported that pathology of basal cell 
carcinoma reveals the presence of a large number of apoptotic bodies in BCC tissue 
[71, 86]. Also, analysis of mitotic and apoptotic indexes showed that BCC has high 
proliferation associated, with high apoptosis which was suggested to contribute to 
the benign nature of this tumor [63]. In harmony with that, our data shows that 
caspase-3 gene expression is up regulated in BCC cancer tissue comparing to all 
other tissue groups, which may predict high apoptotic activity. This finding doesn’t 
contradict with our previously observation of elevated Bcl2 expression. Bcl2 can 
solely impact the intrinsic apoptosis pathway. Besides, Bcl2 effect on apoptosis is 
dependent on BAX/Bcl2 protein ratio [72]. Bax is a pro apoptotic protein from Bcl2 
family, which competes with Bcl2. When in excess, Bax counters Bcl2 activity and 
releases Cytochrome C from the mitochondria, and thus activates caspase-3 [72].   
Active P53 protein up-regulates MDM2 transcription, which in turn, binds and 
deactivates P53 as a feedback inhibition mechanism [87, 88]. Recent research 
revealed interactions between VDR and p53/MDM2 [68, 89]. VDR promoter region 
contains P53 responsive element. MDM2 promoter contains both P53 and VDR 
responsive elements. Both responsive elements were shown to cooperate in MDM2 
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transcription activation [67, 68]. Also, MDM2 is phosphorylated by S6K1, which 
inactivate MDM2 and inhibit its ability to bind P53. This means that the normal down 
regulation of mTOR pathway by VDR would result in reduced MDM2 
phosphorylation. Consequently, this is expected to yield more MDM2 in the nucleus 
to inactivate p53. In our cancer tissue samples, gene analysis revealed that P53 
gene is overexpressed. MDM2 gene was also found to be overexpressed in that 
tissue group in spite of the elevated levels of VDREBP. However, our earlier results 
suggest that the down regulation of mTOR/S6K1 by VDR is diminished in this tissue 
group. Thus VDR overexpression in cancer tissue is not expected to reduce MDM2 
phosphorylation and inactivation. However, further steps to investigate MDM2 
phosphorylation are required to confirm that conclusion. 
Recently, the relation between P53 and VDR was shown to be more 
complicated than it was thought. P53 is a tumor suppressor gene that may get 
inactivated due to a loss of function mutation in many types of cancers[88]. 
However, it was revealed that some mutant P53 acquire oncogenic activity [10]. P53 
gain of function mutations were reported in many types of cancer including skin 
cancer [10].  
Further interrelationship was found between GOF mutantP53 and vitamin D. 
Mutant P53 was found to up-regulate VDR, increase its nuclear localization, and 
facilitate its binding to VDRE [89]. In contrast mutant P53 inhibited VDR down 
regulation of the genes that have inverse VDRE in their promoter. What is more, 
mutant P53 was shown to manipulate VDR transcriptional activity, converting 
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vitamin D from a pro-apoptotic to an anti-apoptotic agent. Consequently, it was 
concluded that P53 status can manipulate the impact of vitamin D on tumor cells 
[89]. Investigating whether the overexpressed P53 in our tissue specimen is a wild 
type or mutant protein is an important future direction. In case P53 is mutated in our 
BCC specimens, testing for possible impact on VDR activity will be the second 
logical step.  
Vascular endothelial growth factor (VEGF) is a vitamin D target gene, which 
contains VDRE in its promoter [70]. Our gene expression analysis of VEGF 
indicated that this gene is over expressed in both cancer and proximal tissue. These 
are the same tissue groups that are overexpressing 1αOHase. However, VEGF up 
regulation is greater and statistically significant in the proximal tissue, which is 
sometimes referred to as “feeding cells”. VEGF protein binds to the VEGFR2 
receptor on the plasma membrane of nearby vascular endothelial cells promoting 
angiogenesis and providing blood supply to the new tumor growth[90]. VEGF 
expression is also up regulated by Ras-MEK-ERK and by PI3-AKT[91]. In our study, 
we have shown that both Ras and AKT are up-regulated in the proximal tissue 
samples. Besides the over expression of both (1αOHase, and 25OHase) vitamin D 
activating enzymes, VDREBP protein that competes with VDR over the response 
elements in the target genes promoter is extremely low in this tissue groups. We 
suggest that these factors may contribute to the observed up regulation of VEGF in 
the proximal tissue group.   
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We tested the expression of three genes related to DNA damage repair in our 
tissue groups. APEX-1 (apurinic/ apyrimidinic endonuclease 1/redox factor1) is a 
key enzyme in Base excision repair; it facilitates the removal of AP sites from the 
damaged DNA region [92]. Apex-1 gene expression is lower in the non-cancerous 
specimens from patients as compared to the cancer tissue. Both proximal and distal 
locations have equal expression of this gene. This may indicate lower BER activity 
in the non-cancerous tissue of BCC patients than in the cancer location.  
GADD45A is another DNA repair gene that was tested in this study. This 
protein regulates  nucleotide excision repair, especially when damage is caused by 
UV radiation [92] . It interacts with the chromatin and aids in recruiting the 
nucleotides and other NER factors [93]. GADD45A expression is the highest in the 
cancer tissue and it shows gradual decrease in the normal tissue. All our tissue 
specimens are excised from locations that are exposed to UV light, specifically head 
and nick, thus UV induced DNA damage is predicted. GADD45 A was shown to be 
directly regulated by VDR at the transcription level as well as the post translational 
modification level [78].  Also, GADD45A is known to be regulated by P53 [92]. Both 
VDR and P53 were shown previously to be over expressed in our cancer tissue 
group. GADD45 was also proposed to contribute to the BER pathway. It was 
suggested that it facilitates Apex-1 interaction with PCNA [92].  
 PARP-1 Protein is involved in many important cellular functions; mainly DNA 
single-strand and double-strand breaks repair, chromatin remodeling, transcription 
regulation, and cell death. Post translational modification can favor one function of 
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PARP-1 over the other [73]. We have seen over expression of PARP-1 gene in the 
cancer tissue over all other tissue groups from cases and controls. Vitamin D is 
known as PARP-1 inhibitor, which contributes to Vitamin D anti-inflammatory 
property[94]. Vitamin D mediated PARP-1inhibition can occur at the expression 
level[74], or via post translational modification [94]. VDR was also shown to inhibit 
PARP-1 cleavage by caspase-3 [34]. Our data is inconclusive in regards to PARP-1 
activity due to its regulation by post-translational modifications. However, taking in 
consideration the expression of the three genes, we predict higher repair activity in 
cancer tissue comparing to other non-cancerous tissue of BCC patients and 
controls. 
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Figure 4.1: Negative regulation of mTOR by vitamin D is lost in 
BCC tissue: results suggest higher activation of Vitamin D and VDR in 
BCC tissue. Protein analysis shows that REDD1 is successfully up-
regulated in cancer tissue despite the elevation in VDREBP. P-4EPB 
protein analysis reveals that it the expected negative regulation to mTOR 
signaling by VDR is absent in the cancer tissue. Point mutation in Kras 
gene was detected in tissue specimens obtained from BCC patients. Our 
results suggest that the lost mTOR regulation by VDR is possibly related 
to the presence of KRas gain of function mutation which results in over 
activation of Ras-PI3K-AKT-mTOR signaling pathway, and hence, 
overcome the inhibition effect of vitamin D. 
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Figure 4.2: Vitamin D over-activation in BCC tissue is not resulting in 
reduction of Hh-Gli pathway signaling: despite the upregulation of vitamin 
D avtivation gene 1α-OHase in BCC tissue samples, Gli 1 expression 
analysis showed significant up-regulation in the cancer tissue specimens 
of BCC patients. The predicted impact of vitamin D in reducing Hh-Gli 
signaling and blocking Gli1 expression was not found in our tissue 
samples. Others showed that a cross talk between PI3K-AKT-mTOR 
pathway and Hh-Gli pathway may be implicated with SMO independent 
activation of the later pathway.  
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Figure 4.3: VDR role in P53-MDM2 regulation: Active P53 protein up-
regulates the transcription of MDM2 protein which in turn binds and 
deactivates P53 as feedback inhibition mechanism. Recent publications 
revealed VDR involvement in this mechanism in their experimental 
model. VDR promoter region contains P53 responsive element, and 
MDM2 promoter contains both P53 and VDR responsive elements which 
were shown to cooperate in MDM2 transcription activation. In our BCC 
tissue specimens, we found that BCC cancer tissue that up regulate 
VDR also show over expression of MDM2 in spite of the elevated levels 
of VDREBP. Also, P53 gene expression was found to be elevated as 
well.  
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS: 
The main goal for this study is to interpret the impact of vitamin D 
status on the onset and progression and possibly treatment of basal cell 
carcinoma. Most of human studies in literature in regards to vitamin D 
and NMSC are epidemiological. Mechanistic studies about BCC are few, 
and mostly are animal models or cell cultures.  
The unique approach for this study involves human tissue 
samples taken from cancer patients and cancer-free individuals from 
southeast Michigan. This study design exclusively distinguishes between 
the behavior of non-cancerous tissue from cancer patient and tissue from 
cancer-free patients. We are also establishing the alterations in the 
genetic profile of patient’s non-cancerous tissue according to their 
location in relation to the cancer. This idea has a great significance in 
understanding factors that may influence the onset and progression of 
the disease, as well as the risk for future recurrence.  
In conclusion, we believe that the anticipated role of vitamin D is 
not conserved in basal cell carcinoma cells. We have observed that 
Vitamin D ability to negatively regulate mTOR and Hedgehog-Gli 
signaling pathways was diminished. In addition, BCC cancer tissue and 
its feeding cells seem to up-regulate vitamin D activation enzymes, 
vitamin D receptor along with its co-activators proposing higher local 
activity of vitamin D in the cancer tissue. 
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In our samples, BCC cancer tissue specimens have acquired a 
gain of function mutation in KRAS gene, with up-regulation in PI3k-AKT-
mTOR pathway. Interestingly, Kras mutation was also observed in the 
cancer-free specimens from BCC patients. We suggested that this 
finding possibly contribute to the observed lack of sensitivity of BCC 
tissue to Vitamin D effect. However, proving causality needs further 
investigation.  
This will be the first planned future direction related to this study. 
This goal can be approached using cell cultures of BCC cells that carry a 
KRAS mutation similar to the one we identified in our tissue samples. 
Our goal will be to show that silencing the mutated KRAS may result in 
down regulation of mTOR pathway in response to adding vitamin D to 
the media.   
P53 was also found to be up regulated in our cancer tissue 
samples. It unknown whether the expressed P53 in these samples is a 
wild type or a mutant form. P53 mutations are common in many types of 
cancers including skin cancers. It was suggested in literature that P53 
status can manipulate the impact of vitamin D [89]. It was shown that this 
impact is related to binding of mutant P53 to VDRE [89]. 
Investigating P53 and its possible interaction with vitamin D in 
BCC is important to understand and interpret our results. Thus, it will be 
a future direction for this study. P53 mutation can be possibly detected 
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by allele specific primer and blocker Real-time PCR. If P53 is 
successfully detected in BCC tissue samples, a mobility shift assay may 
determine binding of P53 to vitamin D response elements in our 
experimental model. Cell cultures can then be used to inspect whether 
silencing the mutant P53 will result in alterations in the cells response to 
vitamin D.  
Our data propose privation of the benefits expected from 
supplementing BCC patients with high doses of vitamin D. However, it 
does not suggest a detrimental effect of vitamin D for those patients. 
Vitamin D possesses a well-characterized immune suppression effect 
[61, 62]. BCC cancer statistics shows an association between 
compromised immune function and high incidence of BCC with worse 
prognosis, especially among people who takes immune response 
weakening medications such as organ transplant patients [2]. Up 
regulation of VD3 1α-OHase was observed in alveolar macrophages 
isolated from lung cancer patients [95]. It was suggested that local 
activation of vitamin D around the cancer may be beneficial for the 
cancer. It possibly prevents possible immune system attacks to the 
cancer cells [95].  
Studying the impact of vitamin D supplementation on the immune 
response of BCC patients and its possible effect on the disease outcome 
makes our second future direction. Achieving this goal can start with 
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isolating immune cells from the cancer and proximal tissue. Isolated cells 
can be studied for 1α-OHase expression, degree of maturation. Actual 
binding of VDR to the inverse response elements in the promoters of the 
target genes that which may deteriorate the maturation, may be detected 
through mobility shift assay.     
Skin cancer is mainly classified as melanoma and non-melanoma 
skin cancer. Non-melanoma skin cancer is classified, in turn, to many 
subtypes including but not limited to basal cell carcinoma, squamous cell 
carcinoma. Many health care professionals tend to generalize their 
findings regarding skin cancer to include all non-melanoma skin cancer 
types.  
We tried to investigate whether our conclusions applies to all 
NMSC. Tissue specimens were collected from three SCC patients. 
Vitamin D metabolism genes were analyzed in comparison to BCC 
specimens. We concluded that BCC and SCC are acquire different 
behavior in regards to vitamin D metabolism, thus generalizing our 
conclusions to NMSC would have been a scientific mistake. However, 
Full assessment of vitamin D possible effect on other types of skin 
cancer such as SCC and MM is another possible future direction for our 
research group.  
New experiments need to be designed and established for that 
purpose. Subject recruitment and sample collection followed by 
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repeating the procedures that were used in studying BCC will be 
repeated with other types of NMSC. 
In conclusion, we suggest that supplementation of Vitamin D to 
BCC patients has no expected benefit. We also propose that the 
outcome of future steps of this this study will have a greater biologically 
significance if we prove a detrimental effect of Vitamin D with respect to 
progression of BCC. If we find that cancer progression and the risk of 
recurrence is modifiable in individuals by selecting the best regimen for 
maintaining adequate levels of vitamin D, the current requirement, and/or 
supplementation of vitamin D recommended by health care providers 
may become outdated. 
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The relationship between Vitamin D and NMSC is not very clear. Most of human 
studies in literature in regards to vitamin D and NMSC are epidemiological which are 
inconsistent and inconclusive. Mechanistic studies about BCC are few, and mostly are 
animal models or cell cultures.  
The main goal for this study is to interpret the impact of vitamin D status on the onset 
and progression and possibly treatment of basal cell carcinoma. Three tissue samples were 
collected from BCC patients (Cancer, Proximal, and Distal), and from cancer-free 
individuals from southeast Michigan. This study design helps identifying alterations in the 
genetic profile of patient’s non-cancerous tissue based on their location in relation to the 
cancer. This idea has a great significance in understanding factors that may influence the 
onset and progression of the disease, as well as the risk for future recurrence.  
We have observed that Vitamin D ability to negatively regulate mTOR and 
Hedgehog-Gli signaling pathways was diminished. In addition, BCC cancer tissue and its 
feeding cells seem to up-regulate vitamin D activation enzymes, vitamin D receptor along 
with its co-activators proposing higher local activity of vitamin D in the cancer tissue. 
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 In conclusion, we believe that the anticipated role of vitamin D is not conserved in 
basal cell carcinoma cells. 
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